[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23318
1. Hori J, Okuyama M, Azumi M, Kato Y, Taniguchi N, Saga Y, Hashimoto H, Kakizaki H, Tamaki G, Nishihara M, Tokumitsu M: [Clinical significance of cystoscopy in transrectal prostate biopsy]. Hinyokika Kiyo; 2006 Mar;52(3):185-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical significance of cystoscopy in patients with benign prostatic hyperplasia or prostate cancer remains open to discussion.
  • We have always performed cystoscopy with prostate biopsy and have discovered bladder cancer in some patients.
  • Among these 43 patients, bladder cancer was found in 11 patients (2.4%), and transurethral resection bladder tumor (TUR-Bt) was performed on all 11 patients.
  • Pathological staging of bladder cancer was pT1 and G2 in all cases.
  • Bladder stones were seen in 13 patients (2.8%), benign bladder tumor in 5 patients (1.1%), urethral polyp in 7 patients (1.5%), urethral stenosis in 6 patients (1.3%) and ureteral stones associated with ureterocele in 1 patient (0.2%).
  • Cystoscopy may be needed at the time of prostate biopsy because: the above-mentioned abnormalities were first discovered on cystoscopy; and the frequency of bladder cancer was 2.4% for the total patient population, and endoscopic surgery was performed.
  • [MeSH-major] Cystoscopy / standards. Incidental Findings. Prostate / pathology. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy / methods. Humans. Male. Middle Aged. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617871.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Pereira SB, Thiel Rdo R, Riccetto C, Silva JM, Pereira LC, Herrmann V, Palma P: [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese]. Rev Bras Ginecol Obstet; 2010 Jun;32(6):273-8
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese].
  • [Transliterated title] Validação do International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) para a língua portuguesa.
  • PURPOSE: To translate, culturally adapt and validate the questionnaire "International Consultation on Incontinence Questionnaire Overactive Bladder" (ICIQ-OAB) for the Portuguese Language.
  • The final version of the ICIQ-OAB was applied together with the previously translated and tested version of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) in 142 male and female patients with irritative urinary symptoms.
  • CONCLUSION: The culturally adapted version of the ICIQ-OAB translated into Brazilian Portuguese presented satisfactory reliability and survey validity and was considered valid for the evaluation of irritative urinary symptoms of Brazilian patients of both genders.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder, Overactive / diagnosis. Urinary Incontinence / diagnosis

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20945012.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] Brazil
  •  go-up   go-down


3. Yagnik V, Chadha A, Chaudhari S, Patel K: Inflammatory myofibroblastic tumor of the urinary bladder. Urol Ann; 2010 May;2(2):78-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the urinary bladder.
  • Inflammatory myofibroblastic tumor (IMT) of bladder is an uncommon benign tumor of bladder, which is of unknown neoplastic potential, characterized by spindle cell proliferation with characteristic fibroinflammatory and pseudosarcomatous appearance.
  • Essential criteria for the diagnosis of IMT are: spindle myoepithelial cell proliferation and lymphocytic infiltrate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882160.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2943686
  • [Keywords] NOTNLM ; Immunohistochemical staining / inflammatory myofibroblastic tumor / spindle myoepithelial cell proliferation
  •  go-up   go-down


Advertisement
4. Sudhakar PJ, Malik N, Malik A: Leiomyoma of bladder. Saudi J Kidney Dis Transpl; 2008 Mar;19(2):232-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyoma of bladder.
  • A case of leiomyoma of urinary bladder, a rare benign tumor, is presented.
  • The clinical presentation, imaging findings and management of this benign tumor are discussed.
  • [MeSH-major] Leiomyoma / radiography. Urinary Bladder Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310873.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Haferkamp A, Hohenfellner M: [Intravesical treatment of overactive bladder syndrome]. Urologe A; 2006 Oct;45(10):1283-8
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravesical treatment of overactive bladder syndrome].
  • [Transliterated title] Intravesikale Therapie des Overactive-bladder-Syndroms.
  • Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic medication.
  • Botulinum toxin type A injections into the detrusor have been shown to increase bladder capacity and to decrease detrusor overactivity for 6 or more months.
  • Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers which results in an increase of functional bladder capacity.
  • Intravesical capsaicin and resiniferatoxin also affect the afferent C fiber innervation of the bladder, leading to a decrease in detrusor overactivity and also an increased bladder capacity.
  • In conclusion, intravesical therapies can provide an alternative treatment for the management of overactive bladder.
  • [MeSH-major] Administration, Intravesical. Cholinergic Antagonists / administration & dosage. Muscarinic Antagonists / administration & dosage. Urinary Bladder, Overactive / drug therapy. Urinary Incontinence / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1995 Nov;102(11):929-30 [8534633.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):60-4; discussion 66 [10767456.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 2):595-7 [1640530.001]
  • [Cites] J Urol. 1989 Jun;141(6):1350-2 [2724432.001]
  • [Cites] J Urol. 2002 Nov;168(5):1897-913 [12394674.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):692-7 [10953127.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):54-7 [2026301.001]
  • [Cites] Int Braz J Urol. 2004 Jan-Feb;30(1):53-8 [15707518.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1239 [1349978.001]
  • [Cites] Curr Urol Rep. 2005 Nov;6(6):429-33 [16238916.001]
  • [Cites] Neurourol Urodyn. 2005;24(3):231-6 [15747344.001]
  • [Cites] J Urol. 2003 May;169(5):1892-5 [12686868.001]
  • [Cites] Arzneimittelforschung. 1998 May;48(5):486-91 [9638316.001]
  • [Cites] BJU Int. 2005 May;95(7):1023-7 [15839924.001]
  • [Cites] J Urol. 2005 Sep;174(3):984-9 [16094019.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1735-40 [15902187.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):88-93; discussion 93-4 [15183552.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Med Assoc Thai. 2003 Sep;86(9):861-7 [14649971.001]
  • [Cites] Urology. 2005 Jul;66(1):82-7 [15992872.001]
  • [Cites] J Urol. 2000 Aug;164(2):340-3 [10893580.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):33-46; discussion 50 [10767450.001]
  • [Cites] J Obstet Gynaecol. 2006 Feb;26(2):141-3 [16483973.001]
  • [Cites] Neurourol Urodyn. 1999;18(5):447-53 [10494116.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1988 Aug;48(8):562-6 [3215450.001]
  • (PMID = 16972089.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Cholinergic Antagonists; 0 / Mandelic Acids; 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A; K9P6MC7092 / oxybutynin
  • [Number-of-references] 26
  •  go-up   go-down


6. De Padua M, Subramanium N: Benign fibrous histiocytoma of the bladder. Indian J Urol; 2007 Jan;23(1):72-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibrous histiocytoma of the bladder.
  • Mesenchymal tumors of the bladder are rare with leiomyoma accounting for most of these.
  • We present a rare case of a bladder benign fibrous histiocytoma in a 52-year-old male.
  • Histology was that of a benign fibrous histiocytoma.
  • To our knowledge, only two cases of this tumor have been reported in the bladder so far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 1999 Jul;17(3):487-505, vii [10410854.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1991 Feb;82(2):312-5 [1645820.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1836-42 [2169999.001]
  • [Cites] Urology. 1985 Apr;25(4):405-8 [2984823.001]
  • [Cites] Am J Surg Pathol. 1990 Sep;14(9):801-9 [2167613.001]
  • [Cites] Am J Surg Pathol. 1982 Sep;6(6):559-64 [6293323.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1982 Sep;90(5):333-7 [6293244.001]
  • [Cites] Urology. 1977 Dec;10(6):593-5 [203077.001]
  • [Cites] J Urol. 1977 Sep;118(3):470-1 [198591.001]
  • [Cites] J Urol. 1976 Jan;115(1):114-5 [173895.001]
  • [Cites] Actas Urol Esp. 2001 Oct;25(9):664-7 [11765552.001]
  • (PMID = 19675769.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721503
  • [Keywords] NOTNLM ; Benign / bladder / fibrous / histiocytoma
  •  go-up   go-down


7. Wang CL, Tsai EM, Liu CM, Wu CH, Long CY: Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure. Gynecol Obstet Invest; 2007;63(1):28-30
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure.
  • However, concomitant resection of a bladder tumor during the TVT procedure is rare.
  • A bladder tumor located in the trigone was found incidentally during cystoscopy.
  • Concomitant resection of the bladder tumor was performed following the TVT procedure.
  • The surgical result of our patient suggests that concomitant resection of a benign intravesical pathology with TVT procedure is safe and effective.
  • [MeSH-major] Cystoscopy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Incontinence, Stress / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864984.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 13
  •  go-up   go-down


8. Okada Y, Arakaki R, Kitahara M, Terada N, Kaneko Y, Oomori K, Nishimura K: [Two cases of the nephrogenic adenoma of the bladder]. Hinyokika Kiyo; 2005 Jul;51(7):467-70
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of the nephrogenic adenoma of the bladder].
  • Nephrogenic adenoma is a relatively rare, benign tumor of the urinary tract.
  • We experienced two cases of nephrogenic adenoma originating in the bladder.
  • Two papillary tumors were found on the bladder.
  • Transurethral resection of the bladder tumor (TUR-Bt) was performed.
  • The second patient was a 72-year-old man who had a history of TUR-Bt for the bladder tumor and a history of left nephroureterectomy for left ureteral tumor.
  • Cystoscopy showed a papillary tumor on the top of the bladder wall and TUR-Bt was performed.
  • In both cases, the histopathological diagnosis was the nephrogenic adenoma.
  • Our cases are the 40th and 41st cases of the nephrogenic adenoma of the bladder reported in the Japanese literature.
  • [MeSH-major] Adenoma / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119812.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


9. Schwalenberg T, Neuhaus J, Horn LC, Alexander H, Zimmermann G, Ho Thi P, Mallock T, Stolzenburg JU: [New insights in the differential diagnosis of bladder pain syndrome]. Aktuelle Urol; 2010 Mar;41(2):107-18
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insights in the differential diagnosis of bladder pain syndrome].
  • [Transliterated title] Neue Erkenntnisse zur Differenzialdiagnostik des Bladder-Pain-Syndroms.
  • The diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is challenging, since pathogenetic mechanisms and the definition of clinical relevant parameters are still under lively discussion.
  • The criteria recently proposed by the European Society for the Study of Interstitial Cystitis (ESSIC) define a collective of patients based on the cardinal symptom of bladder pain which is heterogeneous, and therefore cannot receive standardised consistent therapy.
  • Thus an extended diagnosis based on molecular markers seems to be indicated to render individual pharmacotherapy possible, and to contribute to elucidation of BPS/IC pathogenesis.
  • For this purpose we feel the vital need for taking a bladder biopsy.
  • The diagnosis of BPS/IC should rely on 3 "columns":.
  • Since a significant contribution of the 3 functional units of the bladder to the pathophysiology is most evident, the examinations should ideally include urothelium, lamina propria, and detrusor musculature.
  • [MeSH-major] Cystitis, Interstitial / diagnosis
  • [MeSH-minor] Biopsy. Capillaries / pathology. Capillaries / physiopathology. Chorionic Gonadotropin, beta Subunit, Human / genetics. Cystoscopy. Diagnosis, Differential. Gene Expression / physiology. Humans. Mast Cells / pathology. Mast Cells / physiology. Mucous Membrane / pathology. Mucous Membrane / physiopathology. Nerve Fibers / pathology. Nerve Fibers / physiology. Practice Guidelines as Topic. Receptors, G-Protein-Coupled / genetics. Risk Factors. Urinary Bladder / pathology. Urinary Bladder / physiopathology. Urinary Bladder, Overactive / classification. Urinary Bladder, Overactive / pathology. Urinary Bladder, Overactive / physiopathology. Urothelium / pathology. Urothelium / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart New York.
  • (PMID = 20309783.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Receptors, G-Protein-Coupled
  • [Number-of-references] 52
  •  go-up   go-down


10. Bensalah K, Patard JJ: [Management of T1G3 tumours of the bladder]. Ann Urol (Paris); 2006 Apr;40(2):93-100
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of T1G3 tumours of the bladder].
  • [Transliterated title] Prise en charge des tumeurs de vessie T1G3 management of T1G3 tumours of the bladder.
  • T1G3 tumours are the most aggressive superficial tumours of the bladder, with a high risk of recurrence and progression.
  • Complete endoscopic resection of the tumour is the first diagnostic and therapeutic step in T1G3 management.
  • A second resection should be done at 1 month to avoid residual tumour and misdiagnosis of a muscle infiltrative cancer.
  • As a result of treatment by instillations of Calmette and Guérin bacillus following endoscopic resection, a 5-year survival rate of 80% has been reported, with 50 to 60% of bladder preservation.
  • BCG is the only conservative treatment that has proven effectiveness on both tumour recurrence and progression.
  • Radical cystectomy can be chosen as first line treatment in patients with particularly aggressive tumours.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709007.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  • [Number-of-references] 58
  •  go-up   go-down


11. Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E: [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer]. Arch Esp Urol; 2008 Apr;61(3):377-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
  • [Transliterated title] Empleo del NMP22 Bladder-Chek en el diagnóstico y seguimiento del cáncer de vejiga.
  • OBJECTIVES: The goal of this work is to evaluate the usefulness of NMP22 BladderChek in the diagnosis and follow-up of bladder cancer, comparing it with cystoscopy and urine cytology.
  • METHODS: Group 1: 109 asymptomatic patients on follow up for bladder cancer underwent cystoscopy, cytology and NMP22 BladderChek.
  • RESULTS: Group 1: 9 patients had tumor relapse.
  • Group 2: 12 patients had bladder cancer.
  • CONCLUSIONS: The low sensitivity of NMP22 Bladder-Chek invalidates it as alternative method to cystoscopy in the follow-up of bladder cancer.
  • But it can be recommended for screening in patients without history of bladder cancer but with an increased risk (smokers, patients with dysuria and hematuria).
  • [MeSH-major] Biomarkers, Tumor / urine. Neoplasm Recurrence, Local / diagnosis. Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / pathology. Cystoscopy. Cytodiagnosis. Female. Hematuria / etiology. Hematuria / urine. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Reagent Strips

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581675.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Reagent Strips; 0 / nuclear matrix protein 22
  •  go-up   go-down


12. Aguilera Tubet C, Gutiérrez Baños JL, Antolín Juárez F, Rebollo Rodrigo MH, Portillo Martín JA, Ruiz Izquierdo F, Ballestero Diego R, Martín García B: [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma]. Actas Urol Esp; 2005 Mar;29(3):252-6
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma].
  • [Transliterated title] Estudio comparativo entre cistoscopia, citología urinaria, NMP-22 y un nuevo método, bladder chek, en el seguimiento del cáncer vesical superficial.
  • OBJECTIVE: The goal of this work tries to evaluate the utility of the qualitative determination of NMP-22 in the evaluation of the superficial bladder carcinoma in asymptomatic patients, comparing it with its quantitative determination, the cytology and the cystoscopy.
  • MATERIALS AND METHODS: A simple of urine just voided was taken in 88 asymptomatic patient follow-up for superficial bladder cell carcinoma.
  • This dose was distributed in 3 parts, for performed cytology, for determination of NMP-22, and 4 drops of the third part are added to device bladder chek.
  • Later, we performed cystoscopy and transurethral resection in patients with a suspicion of bladder cancer.
  • RESULTS: 26 patients had tumor relapse and 62 patients were free of disease.
  • The sensitivity for the bladder chek was of 28%, 34.62% for NMP-22, 34.62% for cytology and 100% for cystoscopy.
  • The sensitivity by degree was 25 in G1, 28.57 in G2 and 50 in G3 for Bladder chek; 29.41, 42.86 and 50 for NMP-22; 23.53, 71.43 and 0 for cytology.
  • The sensitivity by stages was 27.7 in Ta-1 and 50 in T2 for Bladder chek; 34.78 and 50 for NMP-22; 39.13 and 0 for the cytology.
  • CONCLUSIONS: The low sensitivity of bladder chek invalidates it like alternative method to the cystoscopy in the follow-up of the superficial asymptomatic bladder cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Cystoscopy. Immunologic Tests. Nuclear Proteins / analysis. Urinary Bladder Neoplasms / diagnosis. Urine / cytology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945249.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


13. Gaunez N, Larré S, Pirès C, Doré B, Wei J, Pfister C, Irani J: [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol; 2010 May;22(6):350-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)].
  • [Transliterated title] Traduction en langue française et validation linguistique de l'auto-questionnaire Bladder Cancer Index évaluant la qualité de vie dans les tumeurs de vessie.
  • OBJECTIVE: Translation and linguistic validation of the French version of Bladder Cancer Index (BCI).
  • MATERIAL AND METHODS: A double-back translation of the original Bladder Cancer Index was performed.
  • Finally, a pilot study followed by an interview was carried out among one woman and five men having bladder cancer.
  • The impact of various bladder cancer treatment on quality of life could hence be assessed and compared.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22541905.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] France
  •  go-up   go-down


14. Thiel DD, Williams BF, Krishna M, Leroy TJ, Igel TC: Robot-assisted laparoscopic excision of bladder wall leiomyoma. J Endourol; 2009 Apr;23(4):579-82; discussion 582
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted laparoscopic excision of bladder wall leiomyoma.
  • Leiomyoma is the most frequent nonepithelial benign tumor of the bladder, and only about 170 cases have been reported in the literature.
  • Most bladder wall leiomyomas are found incidentally and can be clinically followed if imaging and biopsy findings are consistent with the diagnosis.
  • Resection is usually performed for symptomatic or enlarging masses and is indicated if the diagnosis is in question.
  • We demonstrate imaging characteristics, port placement, operative technique, and surgical pathologic findings of the first reported case of robot-assisted laparoscopic resection of a bladder wall leiomyoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335142.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Niu ZB, Yang Y, Hou Y, Chen H, Liu X, Wang CL: Lymphangioma of bladder. Urology; 2010 Oct;76(4):955-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangioma of bladder.
  • Lymphangioma in the bladder is extremely rare.
  • Ultrasonography, computed tomogram, and retrograde urethrography showed a mass that was in the wall of the bladder.
  • The tumor was red and found to be bulging into the bladder on the right lateral wall of the bladder by cystoscopy.
  • A partial cystectomy was performed and histology revealed a lymphangioma of the bladder.
  • This case, to the authors' knowledge, represents the third reported case of lymphangioma of bladder.Lymphangiomas are benign, soft-tissue tumors of lymphatic origin.
  • They rarely affect the urinary system and a location in the bladder is extremely rare.
  • Only 2 cases of lymphangioma of the bladder have been reported worldwide since 1983.
  • The present report describes a patient with a lymphangioma of the bladder and the imaging characteristics of the lesion are reported, including imagings of sonography, computed tomography, retrograde urethrography, and histologic examination.
  • [MeSH-major] Lymphangioma / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494412.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


16. Gómez García I, Molina Burgos R, Fernández Fernández E, Palacio España A, González Chamorro F, Alvarez E, Conde Someso S: [Myofibroblastic tumor of bladder]. Actas Urol Esp; 2005 Jun;29(6):611-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myofibroblastic tumor of bladder].
  • [Transliterated title] Tumor miofibroblástico de vejiga.
  • The myofibroblastic tumor, is a mesenchymal benign tumor of exceptional character, being its localization but habitual it is the lung; while its appearance in the bladder, is exceptional, not existing but of 100 published cases, of this tumor type in the bladder.
  • This tumor type that clinic and radiologics, behave as a wicked tumor.
  • The pathological diagnosis is complex, due to its similarity with the sarcomas, being necessary to appeal to the inmunohistochemics for a I diagnose of certainty.
  • We present a new case of this neoplasm, carrying out a wide bibliographical revision.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092689.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


17. Hsiao CH, Wen YC, Lee LM: Pseudosarcomatous myofibroblastic proliferation of the urinary bladder. J Chin Med Assoc; 2008 Aug;71(8):431-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous myofibroblastic proliferation of the urinary bladder.
  • Pseudosarcomatous myofibroblastic proliferation (PMP) of the bladder is a rare, benign, and proliferative lesion of the submucosal stroma.
  • We report a 38-year-old female patient who was initially diagnosed with urothelial carcinoma of the urinary bladder under intravenous pyelography.
  • Bladder tumor was resected by the transurethral method, and pathology disclosed a picture compatible with pseudosarcomatous myofibroblastic proliferation.
  • However, local recurrence was found 2 months later, and tumor resection was performed again.
  • [MeSH-major] Neoplasms, Muscle Tissue / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772126.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


18. Roy MK, Joarder RH, Suruzzaman M, Kundu KK, Hossain MA, Alam MM, Sutradhar SR: Leiomyoma of the urinary bladder. Mymensingh Med J; 2005 Jul;14(2):209-11
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyoma of the urinary bladder.
  • Benign mesenchymal tumors of the bladder are rare and comprise less than 1% of the all bladder neoplasms.
  • Leiomyoma is the most common type and comprises 35% of these tumors.
  • These tumors may develop in submucosal (63%), intramural (7%) or subserosal (30%) layer, at any region of the bladder.
  • There are asymptomatic cases (19%), which make the diagnosis more difficult.
  • Various examinations were performed in the last 2 years and was diagnosed either prostatic enlargement or bladder tumor.
  • Cystoscopy was not available for confirming the diagnosis.
  • The surgical exploration revealed a well-circumscribed mass at the bladder neck with moderate enlargement of the prostate.
  • The pathological examination revealed a leiomyoma of the bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056215.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


19. Feil G, Stenzl A: [Tumor marker tests in bladder cancer]. Actas Urol Esp; 2006 Jan;30(1):38-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor marker tests in bladder cancer].
  • [Transliterated title] Pruebas de marcadores tumorales en el cáncer de vejiga.
  • The gold standard for detecting bladder cancer is cystoscopy which identifies nearly all papillary and sessile lesions.
  • Urine cytology is the standard non-invasive marker with very high specificity, but unfavourable poor sensitivity for Ta, G1, and T1 bladder tumors.
  • To improve early detection of bladder cancer as well as to monitor treatment response and tumor recurrence, bladder tumor markers are eligible.
  • An ideal bladder cancer test would have the potential to replace or delay cystoscopy in the follow-up of bladder cancer patients.
  • In recent years, the FDA approved non-invasive tumor marker tests ImmunoCyt / uCyt+, BTA TRAK, BTA stat, NMP22, NMP22 BladderChek, and UroVysion have been investigated.
  • The tests demonstrated higher sensitivity for diagnosis of bladder cancer compared to urine cytology.
  • BTA TRAK, BTA stat, NMP22, and NMP22 BladderChek assays are limited by false-positive results in patients with benign urological diseases such as hematuria, urocystitis, renal calculi or urinary tract infections.
  • Due to low specificity BTA TRAK, BTA stat, NMP22, and NMP22 BladderChek should not be used without first ruling out benign or malignant genitourinary disease other than bladder cancer.
  • With the exception of UroVysion achieving 80% sensitivity and 94% specificity, none of these non-invasive tests revealed a high sensitivity and specificity at the same time, which is a main demand to be made on an ideal tumor marker.
  • Insufficient sensitivity along with limited specificity does not allow replacing cystoscopy in diagnosis of bladder cancer or treatment decisions based on a positive test result.
  • [MeSH-major] Urinary Bladder Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703728.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 60
  •  go-up   go-down


20. Herr H, Konety B, Stein J, Sternberg CN, Wood DP Jr: Optimizing outcomes at every stage of bladder cancer: do we practice it? Urol Oncol; 2009 Jan-Feb;27(1):72-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing outcomes at every stage of bladder cancer: do we practice it?
  • Bladder cancer is a heterogeneous disease that can be either relatively benign or highly malignant depending on the grade and stage of the tumor.
  • Determining the best practices for bladder cancer is based on the stage, grade, and presentation of the cancer.
  • Herein we identify four clinical scenarios involving bladder cancer and discuss whether best practice guidelines are available for these clinical scenarios, and if so, how often do we follow these guidelines.
  • [MeSH-major] Medical Oncology / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Cost-Benefit Analysis. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Invasiveness. Outcome Assessment (Health Care). Urology / methods

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111802.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


21. Saunders SE, Conjeski JM, Zaslau S, Williams J, Kandzari SJ: Leiomyoma of the urinary bladder presenting as urinary retention in the female. Can J Urol; 2009 Aug;16(4):4762-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyoma of the urinary bladder presenting as urinary retention in the female.
  • A case of leiomyoma of the urinary bladder, a rare benign tumor, in a 56-year-old female first seen with bilateral flank pain radiating to both groins, is reported.
  • Evaluation with ultrasound, cystoscopy, urodynamics, and cytology contributed to the diagnosis of urinary bladder leiomyoma.
  • Ultrasound detected a mass in the urinary bladder, and it was confirmed by cystoscopy to be a 5 cm to 6 cm bladder mass on the anterior bladder wall.
  • The mass was prolapsing as a ball valve into the urethra at the level of the bladder neck.
  • [MeSH-major] Leiomyoma / complications. Urinary Bladder Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671234.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


22. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS: Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol; 2007 Jun;177(6):2347-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
  • It recently showed clinical efficacy against several benign and malignant skin lesions, including actinic keratosis and basal cell carcinoma.
  • We hypothesized that imidazoquinolines have therapeutic potential against bladder cancer.
  • We determined the in vitro and in vivo effects of imidazoquinolines against bladder cancer cells.
  • MATERIALS AND METHODS: The human and murine J82, T24, TCC-SUP (American Tissue Culture Collection, Manassas, Virginia) and MBT-2 bladder cancer cell lines were cultured in normal culture medium or medium supplemented with imidazoquinoline.
  • In addition, the effects of imidazoquinoline on in vivo bladder tumor growth were determined via intravesical instillation in an orthotopic bladder tumor model in the mouse.
  • RESULTS: A dose dependent decrease in cell viability was observed in all tumor cell lines treated with imidazoquinoline.
  • In in vivo experiments most mice treated with imidazoquinoline showed only an intense inflammatory response with no evidence of tumor, while control mice showed tumor growth.
  • CONCLUSIONS: Imidazoquinolines have potent direct activity against bladder cancer cells by decreasing cell viability and inducing apoptosis and cytokine production.
  • In addition, in vivo data suggest antitumor effects in an orthotopic bladder cancer mouse model.
  • Therefore, imidazoquinolines may have therapeutic potential as a synthetic intravesical agent against bladder cancer.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / pathology. Cell Line, Tumor / drug effects. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509356.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


23. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH: Highly specific urine-based marker of bladder cancer. Urology; 2005 Dec;66(6):1256-60
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly specific urine-based marker of bladder cancer.
  • OBJECTIVES: Bladder cancer represents a major health problem throughout the world, but advances in tumor biomarker development are revolutionizing how physicians diagnose the disease.
  • We previously used an indirect immunoassay to demonstrate that the bladder cancer specific biomarker, BLCA-4, is present in urine samples from patients with bladder cancer, but not in samples from healthy individuals.
  • METHODS: Urine was collected from healthy individuals and from patients with bladder cancer, benign urologic conditions, or prostate cancer.
  • RESULTS: Using a prospectively determined cutoff of an absorbance unit (OD) of 0.04, 67 of the 75 samples from patients with bladder cancer were positive for BLCA-4, resulting in an assay sensitivity of 89%.
  • Also, 62 of the 65 samples from individuals without bladder cancer were negative for BLCA-4, resulting in an assay specificity of 95%.
  • [MeSH-major] Biomarkers, Tumor / urine. Nuclear Proteins / urine. Urinary Bladder Neoplasms / urine. Urologic Diseases / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Urology. 2014 Jun;83(6):1448 [24987756.001]
  • (PMID = 16360453.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BLCA-4 protein, human; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins
  •  go-up   go-down


24. Eandi JA, Asuncion A, Vandewalker KN, Javidan J: Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma. Int J Urol; 2007 Sep;14(9):862-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma.
  • Granular cell tumor of the bladder is exceptionally rare, with only 11 cases reported in the published reports.
  • Pseudoepitheliomatous hyperplasia of the overlying squamous epithelium has been observed in non-bladder granular cell tumors.
  • We herein report the first case of bladder granular cell tumor to exhibit pseudoepitheliomatous hyperplasia.
  • This phenomenon is significant as it may potentially lead to difficulty in the distinction between infiltrative squamous cell carcinoma and pseudoepitheliomatous hyperplasia in cases of granular cell tumor of the bladder.
  • This case also represents the first granular cell tumor to demonstrate colocalization with adenocarcinoma of the bladder.
  • Based on our findings and a review of the published reports, management for granular cell tumor of the bladder should involve a course of local resection combined with active surveillance given its typical benign course, albeit with the potential for local recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Granular Cell Tumor / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760758.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


25. Yadav R, Das AK, Kumar R: Malignant non-functional paraganglioma of the bladder presenting with azotemia. Int Urol Nephrol; 2007;39(2):449-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant non-functional paraganglioma of the bladder presenting with azotemia.
  • Paragangliomas of the urinary bladder are rare tumors representing less than 1% of bladder tumors and are usually benign.
  • We describe a patient with recurrent nonfunctioning paraganglioma of bladder presenting with hematuria and obstructive uropathy due to involvement of ureteroileal anastomoses.
  • Histology confirmed the presence of nests of tumor cells with abundant eosinophilic cytoplasm.
  • Immunohistochemically the tumor cells were strongly positive for chromogranin A.
  • [MeSH-major] Azotemia / etiology. Paraganglioma / complications. Urinary Bladder Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203357.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


26. Preusser S, Diener PA, Schmid HP, Leippold T: Submucosal endocervicosis of the bladder: an ectopic, glandular structure of Müllerian origin. Scand J Urol Nephrol; 2008;42(1):88-90
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Submucosal endocervicosis of the bladder: an ectopic, glandular structure of Müllerian origin.
  • Endocervicosis of the bladder is a rare, benign variant of endometriosis.
  • During placement of a ureteral stent, a cystic tumor in the posterior bladder wall was discovered in a 47-year-old woman with nephroureterolithiasis.
  • CT and MRI revealed a 5 x 1.6 cm(2) mass in the posterior bladder wall protruding into the lumen of the bladder.
  • Transurethral biopsy of the tumor confirmed the diagnosis of endocervicosis.
  • Complete transurethral resection was rejected due to the absence of symptoms and the benign condition of the lesion.
  • [MeSH-major] Cervix Uteri. Choristoma / pathology. Endometriosis / pathology. Urinary Bladder Diseases / pathology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907048.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


27. Ziadi S, Trimeche M, Hammedi F, Hidar S, Sriha B, Mestiri S, Korbi S: Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder. N Am J Med Sci; 2010 Jan;2(1):39-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder.
  • CONTEXT: Brenner tumors of ovary are relatively uncommon neoplasm.
  • Most of them are benign and less than 5% are proliferating or borderline.
  • The association between Brenner tumor of the ovary and papillary urothelial carcinoma of bladder is extremely rare.
  • CASE REPORT: We describe an unusual case of proliferating bilateral Brenner tumor of the ovary with a highly recurrent low-grade papillary urothelial carcinoma of bladder.
  • CONCLUSION: The immunohistopathological similarities of ovarian and bladder tumors and their association in the current case, may be coincidental but may reflect a common initiating event inducing similar pathogenesis changes in the epithelium of both organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1961 Apr;81:743-51 [13684151.001]
  • [Cites] Urology. 2003 Mar;61(3):634-7; discussion 637 [12639661.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):268-71 [16832656.001]
  • [Cites] Cancer. 1979 May;43(5):1830-9 [445369.001]
  • [Cites] Pathologica. 1990 Jan-Feb;82(1077):101-8 [2194158.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(3):233-4 [17624095.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):318-20 [10475132.001]
  • [Cites] Ann Pathol. 1998 Apr;18(2):103-9 [9608862.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2692-7 [6722728.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1972;233:56-66 [5074634.001]
  • [Cites] Cancer. 1972 Jul;30(1):174-86 [5040741.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):582-91 [4005815.001]
  • (PMID = 22624111.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3354386
  • [Keywords] NOTNLM ; Brenner tumor / ovary / urinary bladder / urothelial carcinoma
  •  go-up   go-down


28. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol; 2007 Sep-Oct;25(5):387-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-RNA profiling in kidney and bladder cancers.
  • To study the role of the micro-RNAs in human kidney and bladder cancer, we analyzed the expression profile of 245 micro-RNAs in kidney and bladder primary tumors.
  • METHODS AND MATERIALS: A total of 27 kidney specimens (20 carcinomas, 4 benign renal tumors, and 3 normal parenchyma) and 27 bladder specimens (25 urothelial carcinomas and 2 normal mucosa) were included in the study.
  • Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
  • Of the kidney cancers studied, there was no differential micro-RNA expression across various stages, whereas with increasing tumor-nodes-metastasis staging in bladder cancer, miR-26b showed a moderate decreasing trend (P = 0.082).
  • CONCLUSIONS: Our results show that different micro-RNAs are deregulated in kidney and bladder cancer, suggesting the involvement of these genes in the development and progression of these malignancies.
  • [MeSH-major] Biomarkers, Tumor. Gene Expression Profiling / instrumentation. Kidney Neoplasms / genetics. MicroRNAs / isolation & purification. Microarray Analysis / instrumentation. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826655.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


29. Saito M, Kimoto M, Araki T, Shimada Y, Fujii R, Oofusa K, Hide M, Usui T, Yoshizato K: Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol; 2005 Nov;48(5):865-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers.
  • The aim of the present study is to develop a method of proteomic analysis for urine of patients with bladder cancers.
  • MATERIALS AND METHODS: Urine samples collected from 40 patients with bladder cancers, 32 healthy volunteers, and 7 old volunteers with benign prostate hypertrophy were treated with gelatin-beads as a group-specific affinity carrier.
  • CONCLUSION: The proteomic analysis with gelatin-affinity purification of urine samples is useful not only for the diagnosis of bladder cancers, but also for estimating the extent of tumor invasion.
  • [MeSH-major] Gelatin / chemistry. Proteins / analysis. Proteome / analysis. Urinary Bladder Neoplasms. Urine / chemistry
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chromatography, Affinity / methods. Electrophoresis, Gel, Two-Dimensional / methods. Fibronectins / analysis. Humans. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Peptide Fragments / analysis. Predictive Value of Tests. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964125.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Peptide Fragments; 0 / Proteins; 0 / Proteome; 9000-70-8 / Gelatin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


30. Fu TY, Tu MS, Tseng HH, Wang JS: Overexpression of p27kip1 in urinary bladder urothelial carcinoma. Int J Urol; 2007 Dec;14(12):1084-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of p27kip1 in urinary bladder urothelial carcinoma.
  • OBJECTIVES: Cyclins and cyclin-dependent kinase (CDK) complexes have important regulatory roles during cell cycle progression and can be used as prognostic markers in various kinds of malignant tumors.
  • This study investigated the expression of proliferative cell nuclear antigen (PCNA), p53, Rb, p27(kip1), and cyclin D1 by immunostains in bladder tumors, especially urothelial papilloma, papillary urothelial neoplasm of low malignant potential, and low and high grade urothelial carcinoma, to see if their expression is associated with classification or grading of the urinary bladder urothelial carcinoma.
  • METHOD: Nuclear expression of PCNA, p53, Rb, p27(kip1), and cyclin D1 was determined immunohistochemically in a series of 89 urinary bladder tumor specimens, including 13 papilloma, 15 urothelial neoplasm of low malignant potential, 17 low grade urothelial carcinoma, and 44 high grade urothelial carcinoma.
  • The results of immunoreactivity were analyzed with respect to the associations with tumor grade.
  • RESULTS: Eighty-two percent (38/45) of the p27(kip1) positive tumors were urothelial carcinoma, and the percentage of the p27(kip1) positivity was higher with increasing grade of the urothelial carcinoma (P = 0.011).
  • There was no significant difference in cyclinD1, Rb and PCNA expression between benign, low malignant potential and urothelial carcinoma.
  • CONCLUSION: We first noted an overexpression of p27(kip1) in urinary bladder urothelial carcinoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Intracellular Signaling Peptides and Proteins / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036045.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Cyclin D; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


31. Castillo O, Foneron A, Vitagliano G, Sánchez-Salas R, Díaz M, Fajardo M, Franco C: Bladder leiomyoma: case report. Arch Esp Urol; 2008 Jan-Feb;61(1):87-91
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder leiomyoma: case report.
  • OBJECTIVE: Leiomyoma is a benign lesion which represents 0.04-0.5% of bladder tumors.
  • CT scan showed a 2 cm diameter exophitic lesion at the anterior left lateral bladder wall, which protruded into the perivesical fat.
  • We performed a laparoscopic partial cistectomy locating the tumor and resecting it with simultaneous cystoscopic control, obtaining negative margins.
  • Final pathology reported: Bladder wall leiomyoma, without mitosis or atypia.
  • Immunohistochemistry was positive for Actine and Vimentine stablishing diagnosis.
  • Cd 1 17 (c-kit) was negative and ruled out a Gastrointestinal Stromal Tumor.
  • CONCLUSIONS: Leiomyoma is bladder's most common benign non epithelial tumor.
  • It origins from the smooth muscle bundles and at the urinary tract the most common localizations are kidney and bladder.
  • Clinical presentation depends on tumor size and localization.
  • Ultrasound is the most useful diagnostic tool and the pathological diagnosis is mandatory.
  • Surgery is the treatment of choice and technique depends on tumor size and localization.
  • The laparoscopic approach seems to be an effective alternative in this group of tumors.
  • [MeSH-major] Leiomyoma / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405038.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


32. Rajjayabun PH, Keegan PE, Lunec J, Mellon JK: erbB receptor expression patterns in human bladder cancer. Urology; 2005 Jul;66(1):196-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] erbB receptor expression patterns in human bladder cancer.
  • OBJECTIVES: To investigate expression patterns of erbB receptors in a panel of 58 human bladder tumors.
  • METHODS: Frozen tumor samples from 58 patients with newly diagnosed bladder cancer were collected; 18 had Stage Ta, 20 Stage T1, and 20 had Stage T2 or worse.
  • Seven normal urothelial samples were obtained from patients with benign urologic conditions.
  • The tumor material was probed using conventional immunoblotting and enhanced chemiluminescence.
  • RESULTS: Most tumors exhibited detectable expression of at least one erbB receptor.
  • Compared with other tumors, the T1 samples exhibited the greatest mean levels of erbB-2 protein expression (P = 0.0028).
  • Of the 58 tumors, 10 (17.2%) coexpressed EGFr and erbB-2; this was associated with T1 disease (P = 0.03).
  • CONCLUSIONS: Varied levels of expression of both EGFr and erbB-2 appear to exist in human bladder cancer.
  • These preliminary data do not support erbB-3/4 as major protagonists in this tumor system.
  • The observations presented suggest a role for EGFr and erbB-2 in the development and progression of bladder cancer that should be explored further.
  • [MeSH-major] Receptor, ErbB-2 / biosynthesis. Urinary Bladder Neoplasms / metabolism


33. Lott S, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L: Soft tissue tumors of the urinary bladder Part II: malignant neoplasms. Hum Pathol; 2007 Jul;38(7):963-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue tumors of the urinary bladder Part II: malignant neoplasms.
  • Most bladder tumors arise from the urothelium.
  • However, there are several uncommon but significant malignant bladder lesions that must be differentiated from urothelial carcinomas and from benign lesions of the bladder.
  • The second half of this two-part review will describe rare nonurothelial malignant tumors of the urinary bladder including leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, malignant fibrous histiocytoma (undifferentiated sarcoma), primitive neuroectodermal tumor, malignant peripheral nerve sheath tumor, hemangiopericytoma, and alveolar soft-parts sarcoma.
  • Because the distinction between malignant and benign lesions has significant therapeutic and prognostic implications, key factors for differentiating them are presented.
  • [MeSH-major] Soft Tissue Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Hemangiopericytoma / pathology. Histiocytoma, Malignant Fibrous / pathology. Humans. Immunohistochemistry. Nerve Sheath Neoplasms / pathology. Neuroectodermal Tumors, Primitive / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574946.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


34. Jalpota Y, Tewari V, Madan R: Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):261-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report.
  • Nephrogenic adenoma is a rare benign tumour-like lesion within the urothelial mucosa of the urinary tract.
  • It may be an incidental finding in bladder of a patient presenting with haematuria, dysuria and bladder growth after renal allograft transplant.
  • Clinically it mimics bladder neoplasm.
  • Definite diagnosis is established by histological examination of tumor.
  • Though it attains an extensive spread in bladder mucosa and has a high tendency to recur, the clinical course is benign.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms. Neoplasm Recurrence, Local / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933732.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Coleman JF, Hansel DE: Utility of diagnostic and prognostic markers in urothelial carcinoma of the bladder. Adv Anat Pathol; 2009 Mar;16(2):67-78
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of diagnostic and prognostic markers in urothelial carcinoma of the bladder.
  • Urothelial carcinoma (UCC) of the bladder demonstrates diverse morphologic features, often leading to diagnostic challenges in the discrimination between UCC and benign mimickers of neoplasia, and between primary UCC and secondary neoplasms involving the bladder.
  • The use of ancillary techniques, including panels of immunohistochemical markers, in distinguishing these entities has aided not only in the diagnosis of UCC, but has also provided insight into the molecular pathogenesis and prognostic value of numerous molecular pathways in UCC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism. Urothelium / metabolism
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550368.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 111
  •  go-up   go-down


36. Stejskal D, Humenanska V, Hanulova Z, Fiala R, Vrtal R, Solichova P, Karpisek M: Evaluation of urine N1,N12-Diacetylspermine as potential tumor marker for urinary bladder cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Nov;150(2):235-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of urine N1,N12-Diacetylspermine as potential tumor marker for urinary bladder cancer.
  • BACKGROUND: N1,N12-diacetylspermine, a diacetylpolyamine which was recently identified in urine, appeared to be a useful tumor marker for a number of cancers.
  • No valid data on urine diacetylspermine concentration in patients with urinary bladder cancer exist.
  • AIM: Evaluation of urine N1,N12-diacetylspermine concentrations in individuals with urinary bladder cancer.
  • METHODS: Urine samples were used from 36 patients with urothelial tumors of the urinary bladder and from 30 patients with benign urological diseases.
  • RESULTS: Urine diacetylspermine did not differentiate in individuals with urinary bladder cancer from controls (medians 171.5 vs 143.8, p = 0.64).
  • Its efficacy for urinary bladder cancer detection was not shown.
  • CONCLUSIONS: Urine N1,N12-diacetylspermine is probably not a useful marker for urinary bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Spermine / analogs & derivatives. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17426784.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


37. Prieto MC, Matousek P, Towrie M, Parker AW, Wright M, Ritchie AW, Stone N: Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue. J Biomed Opt; 2005 Jul-Aug;10(4):44006
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue.
  • Prostate samples for this study were obtained by taking a chip at the transurethral resection of the prostate (TURP), and bladder samples from a biopsy taken at transurethral resection of bladder tumor (TURBT) and TURP.
  • Spectra obtained through the bladder and prostate gland tissue, at different time delays after the laser pulse, clearly show change in the spectra as depth profiling occurs, eventually showing signals from the uric acid cell and urea cell, respectively.
  • We show for the first time, using this novel technique, that we are able to obtain spectra from different depths through both the prostate gland and the bladder.
  • This has major implications in the future of Raman spectroscopy as a tool for diagnosis.
  • With the help of Raman spectroscopy and Kerr gating, it may be possible to pick up the spectral differences from a small focus of adenocarcinoma of the prostate gland in an otherwise benign gland, and also stage the bladder cancers by assessing the base of the tumor post resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / diagnosis. Spectrum Analysis, Raman / methods. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Algorithms. Artifacts. Humans. Male. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178640.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Scosyrev E, Trivedi D, Messing E: Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol; 2010 Sep;20(5):404-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Female bladder cancer: incidence, treatment, and outcome.
  • PURPOSE OF REVIEW: Women are generally less likely to develop bladder cancer compared with men; however, once they acquire this disease, they have a less favorable prognosis.
  • In this review, we describe our current understanding of the relationship between sex and bladder cancer incidence and outcomes and discuss the most recent developments in this area of research.
  • RECENT FINDINGS: Despite some evidence suggesting involvement of hormonal factors in bladder cancer carcinogenesis, the exact mechanisms responsible for increased bladder cancer incidence in men are still incompletely understood.
  • It has been hypothesized that women present with more advanced stages (and thus have inferior survival) than men because early signs of bladder cancer in women are often attributed to more common benign conditions.
  • However, recent studies have shown that excess mortality in women persists after adjustment for stage and other tumor characteristics.
  • Women also do not appear to be significantly undertreated for bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms. Women's Health
  • [MeSH-minor] Female. Health Status Disparities. Humans. Incidence. Male. Neoplasm Staging. Risk Assessment. Risk Factors. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592613.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


39. Abbas F, Memon A, Siddiqui T, Kayani N, Ahmad NA: Granular cell tumors of the urinary bladder. World J Surg Oncol; 2007;5:33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the urinary bladder.
  • BACKGROUND: Granular cell tumors (GCTs) are extremely rare lesions of the urinary bladder with only nine cases being reported in world literature of which one was malignant.
  • Generally believed to be of neural origin based on histochemical, immunohistochemical, and ultrastructural studies; they mostly follow a clinically benign course but are commonly mistaken for malignant tumors since they are solid looking, ulcerated tumors with ill-defined margins.
  • MATERIALS AND METHODS: We herein report two cases of GCTs, one benign and one malignant, presenting with gross hematuria in a 14- and a 47-year-old female, respectively.
  • The benign tumor was successfully managed conservatively with transurethral resection alone while for the malignant tumor, radical cystectomy, hysterectomy with bilateral salpingo-oophorectomy, anterior vaginectomy, plus lymph node dissection was done.
  • CONCLUSION: We recommend careful pathologic assessment for establishing the appropriate diagnosis and either a conservative or aggressive surgical treatment for benign or localized malignant GCT of the urinary bladder, respectively.
  • [MeSH-major] Cystoscopy / methods. Granular Cell Tumor / pathology. Granular Cell Tumor / surgery. Neoplasm Invasiveness / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Emergency Service, Hospital. Female. Follow-Up Studies. Hematuria / diagnosis. Hematuria / etiology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1973 Feb;109(2):101-11 [4124410.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1963 Oct;16:1202-13 [14079990.001]
  • [Cites] Br J Urol. 1961 Mar;33:76-9 [13683165.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):373-6 [9659502.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):48-58 [1985501.001]
  • [Cites] Br J Urol. 1985 Feb;57(1):109-10 [2982445.001]
  • [Cites] J Pathol. 1984 Mar;142(3):221-9 [6323661.001]
  • [Cites] Am J Pathol. 1983 Aug;112(2):139-46 [6192721.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1624-8 [6175391.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):239-48 [7189308.001]
  • [Cites] J Urol. 1974 Sep;112(3):343-5 [4368755.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:936-54 [13893237.001]
  • [Cites] Am J Clin Pathol. 1971 Dec;56(6):736-49 [4108241.001]
  • [Cites] Cancer. 1971 Apr;27(4):948-55 [4102365.001]
  • [Cites] Hinyokika Kiyo. 1969 Jul;15(7):505-13 [4310526.001]
  • [Cites] J Urol. 1968 Dec;100(6):735-7 [4301412.001]
  • [Cites] Int J Urol. 2001 Jan;8(1):29-31 [11168695.001]
  • [Cites] BJU Int. 1999 Nov;84(7):871-2 [10532990.001]
  • (PMID = 17355632.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1828733
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


40. Miyamae K, Otsuka T, Otsuka Y, Nagayoshi M, Hamada Y: [Clinical study of bladder tamponade resulting from clots of blood]. Nihon Hinyokika Gakkai Zasshi; 2006 Jul;97(5):743-7
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of bladder tamponade resulting from clots of blood].
  • PURPOSE: There were many case reports about bladder tamponade resulting from clots of blood.
  • However, there were few reports about the clinical study that result from collecting cases of bladder tamponade.
  • Thus, we performed a retrospective study about bladder tamponade resulting from clots of blood that we had managed.
  • MATERIAL AND METHODS: We investigated 20 patients who had bladder tamponade and were consulted at our facility between October 2002 and September 2005.
  • RESULTS: 8 cases took anticoagulant drugs, 6 cases had medical history of cerebral infarction or cardiac infarction, 4 cases took anticholinergic drugs and 9 cases had benign prostate hypertrophy or urethral stricture.
  • Bleeding was due to bladder tumor in 9, prostate cancer in 1, radiation cystitis in 3, chronic cystitis in 1, malignant lymphoma in 1, idiopathic causes in 3 and unknown causes in 2 cases.
  • For the remaining cases, transurethral coagulation and resection of bladder tumor were used as the second line treatment, and furthermore, radical cystectomy was performed in 1 case.
  • CONCLUSION: According to progress aging society, the amounts of taken anticoagulant drugs and the patients who had lower urinary tract dysfunction may increase.
  • It may be suggested that the cases of bladder tamponade resulting from clots of blood without bladder tumor or radiation cystitis tend to increase.
  • [MeSH-major] Blood Coagulation. Hemorrhage / etiology. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898598.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


41. Shim HS, Choi YD, Cho NH: Malignant glomus tumor of the urinary bladder. Arch Pathol Lab Med; 2005 Jul;129(7):940-2
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant glomus tumor of the urinary bladder.
  • We present a case of a malignant glomus tumor arising in the urinary bladder of a 57-year-old woman with metastatic pulmonary nodules who died 2 months later.
  • Pathologically and clinically confirmed malignant glomus tumors are exceedingly rare, especially those that arise in the visceral organs.
  • The present case retained its architectural similarity to a benign glomus tumor and consisted of sheets of highly malignant round cells showing cytoplasmic positivity for smooth muscle actin.
  • On reticulin histochemical staining, we found that reticulum fibrils surrounded individual tumor cells, suggesting cellular investment by basement membrane.
  • We discuss the concept of malignant glomus tumors and emphasize the criteria that distinguish them from other malignant tumors.
  • [MeSH-major] Glomus Tumor / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15974822.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Moyano Calvo JL, Maqueda Marín Mde L, Dávalos Casanova G, Sánchez de la Vega J, Giraldez Puig J, Huesa Ramírez FI, Maestro Durán JL, Ramírez Mendoza A, Morales López A: [Bladder leiomyoma in a 17-year-old male patient]. Arch Esp Urol; 2005 Nov;58(9):954-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder leiomyoma in a 17-year-old male patient].
  • [Transliterated title] Leiomioma vesical en paciente varón de diecisiete años.
  • OBJECTIVES: Bladder leiomyoma is a rare tumor, its frequency being estimated below 1%.
  • METHODS: We report the case of a 17-year-old mole patient presenting with hematuria and lower urinary tract irritative symptoms whose work up discovered two small bladder tumors.
  • RESULTS: After TUR of the lesions the diagnosis of bladder leiomyoma was established; no recurrences have appeared on follow-up.
  • CONCLUSIONS: Bladder leiomyoma is a benign tumor, therefore surgery should be the most conservative.
  • [MeSH-major] Leiomyoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430045.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 8
  •  go-up   go-down


43. Lai Y, Ye J, Chen J, Zhang L, Wasi L, He Z, Zhou L, Li H, Yan Q, Gui Y, Cai Z, Wang X, Guan Z: UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology; 2010 Aug;76(2):514.e6-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UPK3A: a promising novel urinary marker for the detection of bladder cancer.
  • OBJECTIVES: Current methods for reliable detection of bladder cancer have some limitations.
  • Finding better noninvasive methods for detection of bladder cancer is an important topic in urology.
  • We want to evaluate prospectively the early detection power of human uroplakin 3 A (UPK3A) for bladder cancer.
  • METHODS: Urine samples were obtained from 32 healthy volunteers, 44 patients with benign urological disorders and 122 patients with bladder cancer.
  • RESULTS: The urinary UPK3A levels are uniformly elevated in bladder cancer patients than in those of normal volunteers and patients with benign urological disorders, and the differences in the mean urinary UPK3A levels of bladder cancer patients and those of normal individuals or benign urological disorders are statistically significant (P <.01).
  • The sensitivity of urine UPK3A, NMP22, and cytology for detecting bladder cancer were 83%, 58%, and 64%, respectively, whereas specificity was 83%, 75%, and 82%, respectively.
  • CONCLUSIONS: We conclude that individuals with bladder cancer have higher UPK3A values.
  • Our data suggest that urine measurement of UPK3A is a sensitive marker for the detection of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Membrane Glycoproteins / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20346489.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Nuclear Proteins; 0 / UPK3A protein, human; 0 / Uroplakin III; 0 / nuclear matrix protein 22
  •  go-up   go-down


44. Riesz P, Székely E, Törzsök P, Majoros A, Szendroi A, Dombovári P, Romics I: [Can inverted papilloma in urinary bladder be considered as a benign tumor]. Orv Hetil; 2010 Jan 17;151(3):92-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can inverted papilloma in urinary bladder be considered as a benign tumor].
  • [Transliterated title] Jóindulatú daganat-e a húgyhólyag invertált papillomája?
  • Inverted papilloma of the urinary bladder is a rare entity.
  • They aimed to find out the rate of inverted papilloma recurrences, and transformations into malignant bladder cancer.
  • MATERIALS AND METHODS: Thirty patients with histologically proven inverted papilloma were followed after transurethral resection of bladder, which meant urine tests every three months, abdominal ultrasound and cystoscopy.
  • In one case, inverted papilloma and transitiocellular tumor (pTa G1) were detected.
  • In one patient, inverted papilloma was found by control cystoscopy after transurethral resection of bladder (pT1 G2) and local chemotherapy 15 months later.
  • CONCLUSIONS: Based on authors' experience, inverted papilloma of the urinary bladder is a benign lesion, but malignant changes or concomitant transitiocellular tumor may occur, thus follow-up is needed.
  • Although references are not standardized, authors suggest following patients with inverted papilloma as a primary (pTa G1) bladder cancer.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Papilloma, Inverted / pathology. Papilloma, Inverted / surgery. Precancerous Conditions / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061266.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


45. Menéndez V, Fernández-Suárez A, Galán JA, Pérez M, García-López F: Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology; 2005 Feb;65(2):284-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of bladder cancer by analysis of urinary fibronectin.
  • OBJECTIVES: To evaluate the diagnostic efficacy of the analysis of fibronectin in the urine samples of patients with bladder cancer.
  • METHODS: The study included 123 subjects: one group of 68 patients with bladder cancer confirmed by transurethral resection; a second group of 10 patients with benign urologic disease, and a third group of 45 healthy subjects.
  • We carried out the analysis of bladder tumor fibronectin (BTF), cytology, and creatinine in urine, and calculated the BTF/creatinine (BTF/CREA) ratio.
  • The sensitivity of urinary cytology was only 55%, but the specificity was 100%.
  • The patients with bladder cancer had significantly greater levels of BTF and the BTF/CREA ratio than did the healthy subjects (P <0.001) and, in the case of BTF without correcting for creatinine, than did the patients with benign urologic disease (P <0.05).
  • We also found significant differences in the levels of BTF and the BTF/CREA ratio among tumor stages, degree of differentiation, tumor size, multifocal nature, and macroscopic appearance.
  • CONCLUSIONS: Determination of fibronectin could be a useful test in the diagnosis of bladder tumors.
  • Nevertheless, the utility of BTF needs to be studied in a wider way in the presence of other pathologic features concurrent with bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Carcinoma, Transitional Cell / urine. Fibronectins / urine. Neoplasm Proteins / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Creatinine / urine. Humans. Luminescent Measurements. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / urine. Predictive Value of Tests. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Urine / cytology. Urologic Diseases / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708039.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Neoplasm Proteins; AYI8EX34EU / Creatinine
  •  go-up   go-down


46. Ukita S, Koshiyama M, Ohnaka M, Miyagawa N, Yamanishi Y, Nishimura F, Nagura M, Kim T, Hirose M, Shirase T, Kobayashi H, Ozasa H: Retroperitoneal lipoma arising from the urinary bladder. Rare Tumors; 2009;1(1):e13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lipoma arising from the urinary bladder.
  • Retroperitoneal benign lipomas are extremely rare and represent about 2.9% of all primary retroperitoneal tumors.
  • About 80% of the tumors in the retroperitoneal cavities are malignant neoplasms.
  • A diagnosis was correctly made by magnetic resonance imaging (MRI) prior to surgery, and a total tumorectomy was performed.
  • The retroperitoneal lipoma was recognized to have arisen from the urinary bladder.
  • Histological sections revealed a tumor consisting of typical adipose cells without atypia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139884.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994430
  • [Keywords] NOTNLM ; lipoma / magnetic resonance imaging. / ovarian mature cystic teratoma / retroperitoneum / urinary bladder
  •  go-up   go-down


47. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS: A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol; 2007 Dec;178(6):2331-6; discussion 2336
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel resectoscope for transurethral resection of bladder tumors and the prostate.
  • PURPOSE: Transurethral bladder tumor resection is associated with imperfect clinical staging and incomplete tumor removal.
  • Transurethral prostate resection may be complicated by inadvertent damage to the urinary sphincter, bladder neck and trigone.
  • It consists of variably sized cutting loops designed for transurethral resection of bladder tumors and the prostate.
  • To date 80 patients with bladder cancer (38) or benign prostatic hyperplasia (42) have undergone surgery with this instrument at our 3 clinical sites.
  • When used during transurethral bladder tumor resection, lateral resection at the base of the tumor enabled accurate depth of penetration into the bladder wall, which may decrease the risk of bladder perforation and improve pathological assessment of tumor invasion.
  • During transurethral prostate resection this novel tool facilitated dissection of adenoma adjacent to the verumontanum and prostatovesical junction, which may decrease the risk of sphincteric damage and bladder neck injury.
  • Current data suggest that the learning curve is mild, its use is safe and it provides distinct advantages when used for transurethral resection of bladder tumors and the prostate.
  • [MeSH-major] Endoscopes. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Transurethral Resection of Prostate / instrumentation. Urinary Bladder Neoplasms / surgery


48. McKenney JK: An approach to the classification of spindle cell proliferations in the urinary bladder. Adv Anat Pathol; 2005 Nov;12(6):312-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach to the classification of spindle cell proliferations in the urinary bladder.
  • Spindle cell proliferations of the urinary bladder are uncommon but may cause significant diagnostic difficulty resulting from the degree of morphologic overlap between clinically benign and malignant lesions.
  • This review discusses the nomenclature, morphologic criteria, and immunohistochemical features used to classify spindle cell proliferations occurring in the urinary bladder, including those with myofibroblastic, smooth muscle, skeletal muscle, epithelial (sarcomatoid urothelial carcinoma), fibroblastic, and neural differentiation.
  • [MeSH-major] Neoplasms, Muscle Tissue / classification. Neoplasms, Muscle Tissue / pathology. Urinary Bladder Neoplasms / classification. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / classification. Carcinoma / pathology. Fibroma / chemistry. Fibroma / classification. Fibroma / pathology. Humans. Immunohistochemistry. Neurofibroma / chemistry. Neurofibroma / classification. Neurofibroma / pathology. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330928.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 67
  •  go-up   go-down


49. Young RH: Tumor-like lesions of the urinary bladder. Mod Pathol; 2009 Jun;22 Suppl 2:S37-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-like lesions of the urinary bladder.
  • Tumor-like lesions of the urinary bladder are reviewed emphasizing those that are most diagnostically challenging for the pathologist and may result in serious errors in patient care if misinterpreted.
  • The first category considered, pseudocarcinomatous proliferations, represents an area of bladder pathology only recently appreciated as being particularly treacherous because of the extent to which irregular islands of benign epithelial cells may seemingly penetrate the lamina propria and cause confusion with carcinoma.
  • The clinical history may be very important in arriving at the correct diagnosis as is the appreciation that the morphology, although architecturally problematic, is different from that of any of the familiar patterns of invasive carcinoma.
  • [MeSH-major] Urinary Bladder Diseases / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19494852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


50. Zachariou AG, Manoliadis IN, Kalogianni PA, Karagiannis GK, Georgantzis DJ: A rare case of bladder fibroepithelial polyp in childhood. Arch Ital Urol Androl; 2005 Jun;77(2):118-20
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of bladder fibroepithelial polyp in childhood.
  • OBJECTIVE: To present a rare case of a benign polyp in a child.
  • Very few cases of urinary tract fibroepithelial polyps in the bladder are reported in the international literature and they are even less common in children.
  • The patient did not report previous urinary tract disorders.
  • After a thorough laboratory investigation, which included urinalysis, urine culture, ultrasonography, intravenous pyelography and cystoscopy the presence of an exophytic papillary tumor in the bladder was identified.
  • RESULTS: The biopsy set the diagnosis of fibroepithelial polyp, which is a rare benign neoplasm and occurs in patients of nearly all ages.
  • They are rarely found in the bladder, especially in the childhood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146277.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. Yoshimura R, Adachi T, Funao K, Kobayakawa H, Matsuyama M, Tsuchida K, Takemoto Y, Nakatani T: Treatment of bladder tumors and benign prostatic hyperplasia with a new TUR system using physiological saline as perfusate. World J Surg; 2006 Mar;30(3):473-7
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bladder tumors and benign prostatic hyperplasia with a new TUR system using physiological saline as perfusate.
  • We have treated both bladder tumor and benign prostatic hyperplasia cases with this new system.
  • When physiological saline is used as the perfusate, blood electrolyte levels are not greatly changed, even after extensive resection of the bladder wall; as a result, this new system is also cost effective because physiological saline is less expensive than non-electroconductive solutions and requires no counter-electrode.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Sodium Chloride / administration & dosage. Transurethral Resection of Prostate / methods. Urinary Bladder Neoplasms / surgery


52. Chatzidarellis E, Mazaris E, Skolarikos A, Maria D, Mitsogiannis I, Mousiou N, Bisas A: Inflammatory Myofibroblastic Bladder Tumor in a Patient with Von Recklinghausen's Syndrome. Case Rep Med; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory Myofibroblastic Bladder Tumor in a Patient with Von Recklinghausen's Syndrome.
  • Myofibroblastic tumor, also known as inflammatory pseudotumor or pseudosarcoma, is a benign tumor with mesenchymal origin.
  • Bladder location is very uncommon.
  • The radiograph evaluation revealed a bladder tumor, and the pathologic examination following a transurethral resection showed inflammatory myofibroblastic tumor of the bladder.
  • The patient finally underwent a radical cystectomy due to the uncertain pathogenesis of inflammatory myofibroblastic tumor as well as the rarity of cases published on bladder tumors in Von Recklinghausen's patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827396.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2935546
  •  go-up   go-down


53. Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T, Miller K, Müller M: Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer; 2005 Nov 1;117(2):274-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer.
  • The aim of our study was to prospectively evaluate the potential diagnostic value and clinical applicability of quantitative analysis of telomerase subunits gene expression in urine for noninvasive detection of bladder cancer.
  • Expression levels of human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR) were analyzed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in urine samples from 163 subjects with bladder cancer and 237 controls (163 individuals with benign genitourinary diseases; 74 healthy subjects).
  • Quantitative urinary hTR analysis detects bladder cancer with an overall sensitivity of 77.0%, whereas hTERT analysis reached a sensitivity of 55.2%.
  • The majority of undetected tumors were small, low-grade pTa lesions.
  • The specificity of hTR increased to 85.0% in the total population if urinary leukocyte contamination was excluded.
  • These data suggest that quantitative hTR analysis is the most accurate telomerase-based test for bladder cancer detection and has the potential to replace cytology as a noninvasive biomarker for disease diagnosis and follow-up.
  • [MeSH-major] Biomarkers, Tumor / urine. DNA-Binding Proteins / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900578.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Protein Subunits; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


54. Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O: Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol; 2010 Feb;183(2):493-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
  • PURPOSE: Urinary tumor markers that help in the early detection of bladder cancer promise a significant improvement in sensitivity, specificity and convenience over conventional, invasive diagnostic tests.
  • We assessed the diagnostic efficacy of hyaluronidase (HYAL1) and survivin for early bladder cancer detection.
  • MATERIALS AND METHODS: The study included 166 patients diagnosed with bladder carcinoma, 112 with benign bladder lesions and 100 healthy volunteers who served as controls.
  • HYAL1 RNA detected all patients with stages 0 and I bladder cancer (p <0.037).
  • CONCLUSIONS: The detection of urinary HYAL1 and survivin RNA is a promising noninvasive test for bladder cancer early detection.
  • [MeSH-major] Biomarkers, Tumor / genetics. Early Detection of Cancer / methods. Hyaluronoglucosaminidase / genetics. Microtubule-Associated Proteins / genetics. RNA / biosynthesis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20006858.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 63231-63-0 / RNA; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


55. Suttmann H, Retz M, Paulsen F, Harder J, Zwergel U, Kamradt J, Wullich B, Unteregger G, Stöckle M, Lehmann J: Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol; 2008;8:5
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells.
  • BACKGROUND: This study evaluated the cytotoxic and antiproliferative efficacy of two well-characterized members of the Cecropin-family of antimicrobial peptides against bladder tumor cells and benign fibroblasts.
  • METHODS: The antiproliferative and cytotoxic potential of the Cecropins A and B was quantified by colorimetric WST-1-, BrdU- and LDH-assays in four bladder cancer cell lines as well as in murine and human fibroblast cell lines.
  • Scanning electron microscopy (SEM) was performed to visualize the morphological changes induced by Cecropin A and B in bladder tumor cells and fibroblasts.
  • RESULTS: Cecropin A and B inhibit bladder cancer cell proliferation and viability in a dose-dependent fashion.
  • The average IC50 values of Cecropin A and B against all bladder cancer cell lines ranged between 73.29 mug/ml and 220.05 mug/ml.
  • In contrast, benign fibroblasts were significantly less or not at all susceptible to Cecropin A and B.
  • Both Cecropins induced an increase in LDH release from bladder tumor cells whereas benign fibroblasts were not affected.
  • SEM demonstrated lethal membrane disruption in bladder cancer cells as opposed to fibroblasts.
  • CONCLUSION: Cecropin A and B exert selective cytotoxic and antiproliferative efficacy in bladder cancer cells while sparing targets of benign murine or human fibroblast origin.
  • Both peptides may offer novel therapeutic strategies for the treatment of bladder cancer with limited cytotoxic effects on benign cells.
  • [MeSH-major] Anti-Infective Agents / pharmacology. Antimicrobial Cationic Peptides / pharmacology. Antineoplastic Agents / pharmacology. Insect Proteins / pharmacology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Bromodeoxyuridine / analysis. Cell Line, Tumor. Cell Membrane / pathology. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Microscopy, Electron, Scanning. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1404-8 [7751885.001]
  • [Cites] Pept Res. 1994 Sep-Oct;7(5):265-9 [7849420.001]
  • [Cites] Biochim Biophys Acta. 1997 Aug 29;1336(2):171-9 [9305787.001]
  • [Cites] J Pept Res. 1997 Oct;50(4):279-85 [9352466.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Feb;101(1):16-23 [9460495.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jan 26;242(3):608-12 [9464264.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4467-74 [9891511.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cell Mol Life Sci. 2005 Apr;62(7-8):784-90 [15868403.001]
  • [Cites] J Urol. 2005 Jul;174(1):86-91; discussion 91-2 [15947584.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5371-8 [16707464.001]
  • [Cites] Eur Urol. 2006 Jul;50(1):141-7 [16476519.001]
  • [Cites] J Urol. 2000 Apr;163(4):1124-9 [10737480.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):680-4 [10954628.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):597-604 [11309436.001]
  • [Cites] Eur Urol. 2002 Feb;41(2):105-12 [12074395.001]
  • [Cites] J Urol. 2002 Nov;168(5):1964-70 [12394686.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Curr Opin Urol. 2003 Sep;13(5):357-62 [12917511.001]
  • [Cites] J Intern Med. 2003 Sep;254(3):197-215 [12930229.001]
  • [Cites] Eur Urol. 2003 Oct;44(4):423-8 [14499675.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5779-86 [15313920.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Nov;80(21):6475-9 [6579533.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Apr;82(8):2240-3 [3857578.001]
  • [Cites] Biochemistry. 1985 Mar 26;24(7):1683-8 [3924096.001]
  • [Cites] Biochim Biophys Acta. 1991 Mar 18;1063(1):162-70 [2015255.001]
  • [Cites] Eur J Biochem. 1991 Oct 1;201(1):23-31 [1915368.001]
  • [Cites] Curr Opin Immunol. 1992 Feb;4(1):3-7 [1596366.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3534-8 [1319823.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(2):109-15 [8485805.001]
  • [Cites] J Membr Biol. 1997 Apr 1;156(3):197-211 [9096062.001]
  • (PMID = 18315881.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antimicrobial Cationic Peptides; 0 / Antineoplastic Agents; 0 / Insect Proteins; 80451-04-3 / cecropin A; 80451-05-4 / cecropin B protein, Insecta; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2276511
  •  go-up   go-down


56. Tiwari P, Tripathi A, Vijay M, Mitra B, Kumar S, Pal DK, Kundu AK: Inverted papilloma of the urinary bladder: Rigorous surveillance needed? An Indian experience. Indian J Cancer; 2010 Oct-Dec;47(4):418-23
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted papilloma of the urinary bladder: Rigorous surveillance needed? An Indian experience.
  • AIMS: Inverted papilloma (IP) is an uncommon benign neoplasm of the urinary tract.
  • In this study, we review all cases of urinary bladder IP in our institution and determine the need for strict follow-up.
  • MATERIALS AND METHODS: We included consecutive patients from August 2004 to August 2008 with IP of the urinary bladder in this study who did not have prior or concurrent urothelial carcinoma.
  • No patient had a synchronous or previous bladder tumor.
  • All were solitary tumors except one, most commonly found at the bladder neck and trigone.
  • CONCLUSIONS: We conclude that when diagnosed by strictly defined criteria, IP as benign urothelial neoplasm was with extremely low incidence of recurrence and good prognosis.
  • It does not seem to be a risk factor for TCC, especially if located in the bladder.
  • [MeSH-major] Papilloma, Inverted / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21131756.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


57. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K: Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology; 2008;75(3-4):145-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
  • AIMS: Superficial bladder cancer is a highly recurrent disease, with progression to muscle invasiveness occurring in 15-30% of cases.
  • Promoter hypermethylation in a panel of tumour suppressor genes involved in cell cycle control, apoptosis and DNA repair was analyzed in superficial bladder tumours in order to evaluate the suitability of epigenetic biomarkers for an earlier prediction of the aggressive course of the disease.
  • METHOD: Promoter hypermethylation in p16, RARbeta, RASSF1A, DAPK, and MGMT genes was analyzed in 58 cases with superficial bladder cancer and 2 cases with benign urological disease using methylation-specific PCR.
  • RESULTS: Promoter hypermethylation was frequently detected in RARbeta, RASSF1A and DAPK genes, and 62% of bladder tumours exhibited hypermethylation in at least one gene.
  • The overall frequency of hypermethylation and the number of genes involved increased with tumour stage, grade and muscle invasiveness.
  • Aberrant methylation of RASSF1A and RARbetawas predominant (p < 0.05) in muscle-invasive tumours and high-grade tumours, respectively.
  • CONCLUSION: The results suggest analysis of promoter hypermethylation as a valuable biomarker for prognosis of the aggressive course of disease in bladder cancer.
  • [MeSH-major] DNA Methylation. Genes, Tumor Suppressor. Promoter Regions, Genetic / genetics. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Muscle Neoplasms / genetics. Muscle Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18824877.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


58. Sun Y, He DL, Ma Q, Wan XY, Zhu GD, Li L, Luo Y, He H, Yang L: Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl); 2006 Nov 5;119(21):1763-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of seven screening methods in the diagnosis of bladder cancer.
  • BACKGROUND: We compared the validity (evaluated by sensitivity and specificity), reliability (evaluated by reproducibility) and yield (evaluated by predictive value, examining complexity and cost) of individual and combined tests for bladder tumour antigen stat (BTAstat), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), survivin, CD44v6, vascular endothelial growth factor (VEGF), and voided urine cytology (VUC) in detecting bladder cancer.
  • And at the same time we evaluated the clinical value of these seven detecting methods in the diagnosis of bladder cancer.
  • METHODS: The six markers and VUC were detected in the urine of cancer group (151 patients with bladder cancer) and two control groups (50 patients with benign urological diseases and 50 healthy controls).
  • RESULTS: There was a significant difference between bladder cancer group and the two control groups.
  • CONCLUSIONS: All the markers have obvious clinical value in diagnosis of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / analysis. Antigens, Neoplasm / analysis. Female. Glycoproteins / analysis. Humans. Hyaluronic Acid / analysis. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / analysis. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Nuclear Proteins / analysis. Sensitivity and Specificity. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097029.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / nuclear matrix protein 22; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


59. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM: Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol; 2010 Dec;27(4):1286-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
  • Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity.
  • The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer.
  • This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological disorders and 47 healthy volunteers.
  • Our results indicate that fibronectin had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, mutant p53 had superior specificity compared to VUC and fibronectin.
  • Mutant p53 is associated with disease recurrence and hence it has a significant prognostic role in bladder cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Fibronectins / urine. Mutation / genetics. Tumor Suppressor Protein p53 / genetics. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Case-Control Studies. Cystoscopy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. ROC Curve. Schistosoma mansoni / pathogenicity. Schistosomiasis / diagnosis. Schistosomiasis / genetics. Schistosomiasis / urine. Sensitivity and Specificity. Survival Rate. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012564.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Kang JU, Koo SH, Jeong TE, Kwon KC, Park JW, Jeon CH: Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet; 2006 Jan 1;164(1):32-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma.
  • Conventional urine cytology has a poor prognostic performance for detecting bladder cancer, particularly for low-grade tumors.
  • Fluorescence in situ hybridization (FISH) for chromosomes altered in bladder cancer and testing for antigens selectively expressed in tumors are promising alternatives.
  • This study investigated the use of FISH for detecting aneuploidy of chromosomes 3, 7, 17, and 9p21 and reverse transcriptase PCR (RT-PCR) for the expression of melanoma associated antigen (MAGE) genes for the diagnosis of bladder cancer in voided urine specimens.
  • The two techniques were compared with cystoscopic bladder biopsy results in 47 patients with urothelial cancer and 15 patients with benign prostatic hyperplasia.
  • The sensitivity of FISH increased with histologic grade and stage of the tumors, correctly identifying 77.8% of pTa and pTis, 94.1% of pT1, and 100% of Pt2-4 tumors.
  • MAGE, however, showed a decreased sensitivity in high grade advanced tumors; it was positive in 66.7% of pTa and pTis, 70.6% of pT1, and 50% of Pt2-4 tumors.
  • Combined FISH and MAGE RT-PCR testing may offer a promising alternative to conventional urine cytology in screening high-risk populations and in monitoring bladder cancer patients for recurrent tumor.
  • [MeSH-major] In Situ Hybridization, Fluorescence. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Female. Humans. Male. Melanoma-Specific Antigens. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364760.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


61. Kumar A, Bhatti SS, Sharma S, Gupta SD, Kumar R: Inflammatory pseudotumor of urinary bladder - a diagnostic and management dilemma. Int Urol Nephrol; 2007;39(3):799-802
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of urinary bladder - a diagnostic and management dilemma.
  • Inflammatory pseudotumors (IPT) are uncommon, benign, non-epithelial tumors of the urinary bladder.
  • The transititional cell carcinoma constitutes 90% of malignant epithelial tumors of urinary bladder.
  • Large, endoscopically unresectable tumors require radical surgery.
  • IPT resemble such tumors, morphologically, radiologically and clinically.
  • The benign nature of this tumor warrants conservative surgical management, either transurethral resection or partial cystectomy.
  • Awareness of this entity and its inclusion in the differential diagnosis may prevent unnecessary radical surgery.
  • We report an unusual case of inflammatory pseudotumor of urinary bladder because of its diagnostic and management dilemma.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / surgery. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333528.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


62. Wiedemann A, Jaussi R, Rabs U: [Isolated neurofibromatosis of the urinary bladder. A rare cause of recurrent cystitis]. Urologe A; 2006 Feb;45(2):215-8
MedlinePlus Health Information. consumer health - Neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated neurofibromatosis of the urinary bladder. A rare cause of recurrent cystitis].
  • [Transliterated title] Die isolierte Neurofibromatose der Harnblase. Eine seltene Ursache rezidivierender Zystitiden.
  • Neurofibromas of the urinary bladder occur as isolated phenomena or as part of generalized neurofibromatosis or von Recklinghausen's disease.
  • This benign mesenchymal tumor can be the cause of subvesical obstruction, hematuria or chronic cystitis.
  • Our case of isolated extended neurofibromatosis of the urinary bladder was diagnosed in a 19-year-old girl with an 8-year history of chronic cystitis.
  • [MeSH-major] Cystitis / diagnosis. Cystitis / etiology. Neurofibromatoses / complications. Neurofibromatoses / diagnosis. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2001 Nov;8(11):645-7 [11903695.001]
  • [Cites] Eur Urol. 1995;27(3):261-3 [7601195.001]
  • [Cites] Monatsschr Kinderheilkd. 1989 May;137(5):289-92 [2500591.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):505-13 [10430260.001]
  • [Cites] J Urol. 1990 Sep;144(3):742-3 [2117673.001]
  • [Cites] Hinyokika Kiyo. 1987 Jan;33(1):125-32 [3107355.001]
  • [Cites] Clin Radiol. 1985 Sep;36(5):537-8 [3935357.001]
  • [Cites] Urol Int. 2002;69(2):156-9 [12187050.001]
  • (PMID = 16175398.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Patrozos K, Westphal J, Trawinski J, Wagner W: [Total laparoscopic excision of a leiomyoma of the urinary bladder -- a case report]. Aktuelle Urol; 2005 Feb;36(1):58-60
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total laparoscopic excision of a leiomyoma of the urinary bladder -- a case report].
  • INTRODUCTION: Leiomyoma of the urinary bladder is a rare, benign tumor of mesenchymal origin.
  • Besides open surgery and transurethral resection of small, submucosal tumors, laparoscopic excision is an effective therapeutical option with a low complication rate.
  • CASE REPORT: We report the medical history of a 36-year-old woman suffering from a leiomyoma of the urinary bladder and the therapy through laparoscopic excision.
  • CONCLUSIONS: Laparoscopic removal of urinary bladder leiomyomas is a suitable alternative to common therapeutical procedures.
  • [MeSH-major] Cystectomy. Laparoscopy. Leiomyoma / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Cystoscopy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation. Urinary Bladder / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732006.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Hungerhuber E, Bach E, Hartmann A, Frimberger D, Stief C, Zaak D: Adenocarcinoma of the bladder following nephrogenic adenoma: a case report. J Med Case Rep; 2008;2:164

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the bladder following nephrogenic adenoma: a case report.
  • INTRODUCTION: Nephrogenic adenomas are generally considered to be benign lesions, but there remains a risk for malignant transformation.
  • We report a case of post-traumatic nephrogenic adenoma in a young patient without immunosuppression, which transformed into an adenocarcinoma of the bladder.
  • CASE PRESENTATION: A 25-year-old man had a traumatic bladder perforation caused by a car accident.
  • After physical recovery from the accident, he developed a neurogenic bladder and recurrent urinary tract infections.
  • He presented with nephrogenic adenoma of the bladder 18 months after the accident.
  • The initial pathologic findings were benign, however, the last resection revealed that the former benign adenoma had transformed into a moderately differentiated adenocarcinoma of the bladder (tumor present but no invasion, multifocal, no lymph nodes involved, no metastasis, grade 2).
  • He subsequently underwent radical cystectomy and has remained tumor-free for the last 4 years.
  • However, patients with nephrogenic adenoma under immunosuppression and patients with neurogenic bladder dysfunction appear to be at a higher risk of developing bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1988 Jan;139(1):130-1 [3121867.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1987 Mar;29(3):237-41 [3548004.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):268-75 [3706613.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] J Urol. 1984 Aug;132(2):263-5 [6737573.001]
  • [Cites] J Urol. 1981 Dec;126(6):824-6 [6798226.001]
  • [Cites] J Urol. 1996 Jul;156(1):41-4 [8648834.001]
  • [Cites] Urology. 1997 Nov;50(5):690-6 [9372876.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):117-22 [11954029.001]
  • [Cites] N Engl J Med. 2002 Aug 29;347(9):653-9 [12200552.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2381-2 [14634422.001]
  • [Cites] J Urol. 1950 Nov;64(5):657-70 [14785074.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):117-20 [16360424.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1231-7 [17667548.001]
  • [Cites] Northwest Med. 1949 Mar;48(3):182-5 [18114097.001]
  • [Cites] J Urol. 1988 Jan;139(1):45-7 [3275801.001]
  • (PMID = 18485239.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2396656
  •  go-up   go-down


65. Pu RT, Laitala LE, Clark DP: Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol; 2006 Sep-Oct;50(5):499-506
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation profiling of urothelial carcinoma in bladder biopsy and urine.
  • STUDY DESIGN: Thirty-three bladder specimens were analyzed for the DNA p16INK4a, RASSF1, APC, GSTP, E-Cad and CyclinD2 genes to determine if there is a difference in gene methylation between benign and malignant cases.
  • RESULTS: We found methylated genes in 18% benign, 37% urothelial carcinoma in situ and 93% infiltrating urothelial carcinoma cases (p = 0.001).
  • Methylation profiles from the 18 urine samples revealed a significantly higher prevalence of methylated genes in carcinoma cases than benign cases (100% vs. 50%, p = 0.025).
  • We analyzed methylation profiles in 37 cytologically atypical urine samples with malignant or benign diagnosis on surgical follow-up andfound that only APC (55% in malignant vs. 0% in benign, p=0.025) and CyclinD2 were differentially methylated (35% in malignant vs. 0% in benign, p=0.2) while p14ARF, p16INK4a, RASSF1, GSTP and E-Cad had similar methylation profiles.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / genetics. DNA Fingerprinting / methods. DNA Methylation. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / genetics. Urothelium / pathology
  • [MeSH-minor] Aged. Anaphase-Promoting Complex-Cyclosome. Cadherins / genetics. Cadherins / metabolism. Cyclin D2. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Cyclins / genetics. Cyclins / metabolism. DNA / genetics. DNA / urine. Diagnostic Errors / prevention & control. False Negative Reactions. Feasibility Studies. Genetic Markers / genetics. Humans. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Protein p14ARF / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Ubiquitin-Protein Ligase Complexes / genetics. Ubiquitin-Protein Ligase Complexes / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017434.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cadherins; 0 / Cyclin D2; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclins; 0 / Genetic Markers; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 9007-49-2 / DNA; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


66. Stejskal D, Fiala RR: Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma; 2006;53(4):343-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer.
  • No valid information about serum or urine clusterin concentration in patiens with bladder cancer exists.
  • Aim of our paper was evaluation of the urine and serum clusterin concentrations in individuals with bladder cancer.
  • Blood and urine samples were used from 43 patients with urothelial tumors of the urinary bladder and from 50 patients with benign urological diseases.
  • Serum clusterin was higher in individuals with bladder cancer (means 185,812.5 vs 171,946.5 kU/l, p=0.04).
  • Sensitivity for bladder cancer detection was 73% and specificity 55% (AUC 0.63); efficacy was not sufficient.
  • Urine values of clusterin were higher in individuals with bladder cancer (197.2 vs 67.7, p=0.0007).
  • Sensitivity for bladder cancer detection was 49% and specificity 92% (AUC 0.75, LR+ 6.1, PPV+ 84%); diagnostic efficacy was sufficient.
  • In conclusion, serum and urine clusterin can differ between bladder cancer patients and the control group.
  • Urine clusterin could be the possible laboratory marker of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / urine. Clusterin / blood. Clusterin / urine. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830064.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Clusterin
  •  go-up   go-down


67. Zhou M, Reuther AM, Levin HS, Falzarano SM, Kodjoe E, Myles J, Klein E, Magi-Galluzzi C: Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor. Mod Pathol; 2009 Mar;22(3):385-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor.
  • The independent prognostic importance of microscopic bladder neck involvement by prostate cancer in radical prostatectomy is questionable.
  • We studied a cohort of 1845 patients to determine the significance of microscopic bladder neck involvement.
  • Bladder neck involvement was defined as prostate cancer present within the coned bladder neck.
  • We further categorized the cases as 'true bladder neck involvement' and 'false bladder neck involvement.
  • ' True bladder neck involvement required prostate cancer within thick smooth muscle bundles without intermixed benign prostatic glands.
  • False bladder neck involvement was characterized by prostate cancer intermixed with benign prostatic glands.
  • Bladder neck involvement was analyzed in relation to preoperative serum prostate-specific antigen (PSA) level, extraprostatic extension, seminal vesicle involvement, positive surgical margin, lymph node involvement, radical prostatectomy Gleason score, and tumor volume.
  • Of the 90 patients (4.9%) with microscopic bladder neck involvement, 63 were further classified as true bladder neck involvement and 27 as false bladder neck involvement.
  • In univariate model, both types of bladder neck involvement (P<0.001), true (P<0.001), and false (P=0.040), were significantly associated with increased PSA-recurrence risk compared to bladder neck negative cases.
  • In multivariate model the PSA-recurrence relative risk associated with bladder neck involvement (true or false) was not a significant independent prognostic factor.
  • The time to biochemical recurrence in patients with bladder neck involvement was similar to that of pT2 with positive surgical margin or pT3a with negative surgical margin patients (Kaplan-Meier curves).
  • Bladder neck involvement was associated with other adverse pathologic features, but was not an independent predictor of PSA recurrence.
  • In view of the previous and current data, the staging system for bladder neck involvement should be revised and patients may be best categorized as having pT3a disease.
  • [MeSH-major] Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043400.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


68. Riesz P, Lotz G, Páska C, Szendrôi A, Majoros A, Németh Z, Törzsök P, Szarvas T, Kovalszky I, Schaff Z, Romics I, Kiss A: Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res; 2007;13(3):187-94
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of bladder cancer from the urine using fluorescence in situ hybridization technique.
  • The authors report on their first experiences with the UroVysion fluorescence in situ hybridization (FISH) kit developed for the detection of bladder cancer.
  • We aimed to evaluate the utility of UroVysion test in the light of the histological diagnosis.
  • Urine samples from 43 bladder cancer patients and 12 patients with no or benign alterations were studied using a new application of FISH technique: the UroVysion reagent kit.
  • Therefore, the technique could well fit into the diagnostic process of bladder carcinomas.
  • Statistical analyses showed significant correlation between tumor progression and the severity of the genetic alterations detected by this FISH technique.
  • Furthermore, positive correlation was found between tumor grade and the proportion of tumor cells showing genetic abnormality.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology. Urine / cytology
  • [MeSH-minor] Case-Control Studies. Chromosome Aberrations. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 7. Cystoscopy / methods. Diagnosis, Differential. Humans. Sensitivity and Specificity. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922047.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Konety BR: Molecular markers in bladder cancer: a critical appraisal. Urol Oncol; 2006 Jul-Aug;24(4):326-37
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers in bladder cancer: a critical appraisal.
  • The diagnosis of both primary and recurrent bladder tumors currently relies upon the urine cytology and cystoscopy.
  • Prognostication of bladder cancer is largely based on pathologic tumor grade and stage.
  • Over the past 2 decades, there is accumulating evidence that like many other cancers, bladder cancer, too, has a distinct molecular signature that separates it from other cancers and normal bladder tissue.
  • Bladder tumors of different grades and stages even possess unique, and specific genotypic and phenotypic characteristics.
  • Although recognition of several of these molecular alterations is possible by analyzing tumor tissue, urine, and serum samples, few if any of these "molecular markers" for bladder cancer are widely used in clinical practice.
  • In this review of molecular markers for bladder cancer, effectiveness of markers in each of these categories that are identifiable in the urine of patients with bladder cancer was examined.
  • Many of the diagnostic markers appear to hold an advantage over urine cytology in terms of sensitivity, especially for the detection of low-grade superficial tumors.
  • This result is more commonly observed in patients with concurrent bladder inflammation or other benign bladder conditions.
  • Further studies involving larger numbers of patients are required to determine their accuracy and widespread applicability in guiding treatment of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818187.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nuclear matrix protein 22; 68238-35-7 / Keratins; 9004-61-9 / Hyaluronic Acid; EC 2.7.7.49 / Telomerase
  • [Number-of-references] 179
  •  go-up   go-down


70. Ueda Y, Kawaguchi R, Takiuchi H, Kokura K, Yoshimoto T, Mitsui Y, Suzuki T, Jun Q, Higuchi Y, Maruyama T, Kondoh N, Nozima M, Yamamoto S, Shima H: [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek]. Hinyokika Kiyo; 2009 Feb;55(2):71-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
  • We compared the sensitivity of Bladder Chek NMP22 with that of urine cytology in bladder cancer patients.
  • Further, we evaluated the usefulness of Bladder Chek NMP22 in patients with benign diseases such as cystitis, urolithiasis, and benign prostate hyperplasia (BPH) and examined how blood cells in urine samples affect the results of Bladder Chek NMP22.
  • Of 77 bladder cancer patients, Bladder Chek NMP22 showed positive in 46.8%, while urine cytology in 33.8% (p = 0.16).
  • Bladder Chek NMP22 and urine cytology showed positive in 31.8 and 0.0% in G1 (p = 0.004), 51.2 and 46.3% in G2 (p = 0.66) and 57.1 and 50% in G3 (p = 0.71); 44.4 and 88.9% in Tis (p = 0.052), 25.6 and 15.4% in Ta (p = 0.27), 72.2 and 33.3% in T1 (p = 0.02) and 81.8 and 54.5% in T2 or higher (p = 0.18), respectively.
  • In bladder cancer patients with microscopic hematuria or pyuria, the positive rates of Bladder Chek NMP22 were 82.1 and 73.1%, respectively, whereas they were 26.5% (p < 0.001) and 33.3% (p = 0.002), respectively, in those without hematuria or pyuria.
  • In 36 cystitis, 20 urolithiasis, and 19 BPH patients, the positive rates of Bladder Chek NMP22 were 58.3, 25.0 and 5.5%, respectively.
  • Bladder Chek NMP22 showed higher sensitivity for detection of bladder cancer, especially in low-grade and low-stage cancers than urine cytology, but the result was likely affected by blood cells in urine samples.
  • Thus, although Bladder Chek NMP22 may be less useful as the first device for screening of urothelial cancer in patients with hematuria or pyuria, it may show results of high quality when used in patients with negative urine cytology after excluding benign diseases.
  • [MeSH-major] Biomarkers, Tumor / urine. Blood Cells / cytology. Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis. Urine / cytology
  • [MeSH-minor] Aged. Female. Hematuria / urine. Humans. Male. Pyuria / urine. Reagent Kits, Diagnostic. Sensitivity and Specificity. Urologic Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301610.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; 0 / nuclear matrix protein 22
  •  go-up   go-down


71. Hotakainen K, Bjartell A, Sankila A, Järvinen R, Paju A, Rintala E, Haglund C, Stenman UH: Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol; 2006 Jan;28(1):95-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
  • Tumor-associated trypsin inhibitor (TATI) is a marker of mucinous ovarian carcinoma, but it is also widely expressed in other malignant tumors and normal human tissues.
  • Elevated serum concentrations of TATI are of prognostic value in ovarian, kidney, and bladder cancer.
  • Tumor-associated trypsin is co-expressed with TATI in many malignancies and is thought to be involved in tumor invasion.
  • TATI mRNA has been shown to be overexpressed in bladder cancer.
  • We therefore studied whether trypsinogen expression also can be detected in bladder cancer and how this and TATI expression are associated with the clinicopathological characteristics of the tumors.
  • We used RT-PCR, in situ hybridization and immunohistochemistry to detect trypsinogen- and TATI mRNA and protein in tissue samples from 28 bladder cancer patients and ten benign urothelia.
  • TATI expression was detected in all benign tissues and non-invasive tumors.
  • However, the expression was lower in the muscle-invasive tumors (pT2; n=5), whereas trypsinogen expression was seen in all but one non-invasive tumor.
  • We conclude that trypsinogen is expressed in both malignant and benign bladder epithelium, whereas TATI expression decreases with increasing stage and grade of the tumor.
  • This may suggest that a balanced expression of TATI and trypsinogen is required in normal tissue and that this balance is disrupted during tumor progression.
  • [MeSH-major] Trypsin Inhibitor, Kazal Pancreatic / biosynthesis. Trypsinogen / biosynthesis. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327984.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic; 9002-08-8 / Trypsinogen
  •  go-up   go-down


72. Pruthi RS, Lentz AC, Sand M, Kouba E, Wallen EM: Impact of marital status in patients undergoing radical cystectomy for bladder cancer. World J Urol; 2009 Aug;27(4):573-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of marital status in patients undergoing radical cystectomy for bladder cancer.
  • PURPOSE: Married (vs. unmarried) individuals have improved health status and longer life expectancies in a variety of benign and malignant disease states, including prostate, breast, head/neck, and lung cancers.
  • We sought to evaluate a cohort of patients undergoing cystectomy for bladder cancer to evaluate the impact of marital status on demographic, peri-operative, and pathological outcomes in order to better understand the factors which may contribute to the survival differences observed.
  • METHODS: Two-hundred and two patients underwent radical cystectomy and urinary diversion for bladder cancer.
  • CONCLUSIONS: In patients undergoing cystectomy for bladder cancer, married individuals appear to have improved pre-operative laboratory variables, shorter hospitalization, and improved pathological outcomes versus unmarried patients in our case series.
  • These findings may support the evidence (observed in other tumor types and other disease states) that married persons present earlier than unmarried individuals, and this may help explain the improved survival outcomes that have been observed in married patients with bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Marital Status. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19219612.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


73. Lott S, Lopez-Beltran A, Maclennan GT, Montironi R, Cheng L: Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol; 2007 Jun;38(6):807-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential.
  • Most bladder tumors arise from the urothelium.
  • However, there are several uncommon but significant bladder lesions that must be differentiated from urothelial carcinomas.
  • These include both benign and malignant spindle cell lesions.
  • The first half of this 2-part review will describe benign myofibroblastic proliferations including inflammatory myofibroblastic tumor and postoperative spindle cell nodule; benign neoplasms including leiomyoma, hemangioma, neurofibroma, and schwannoma; and tumors of uncertain malignant potential including paraganglioma, granular cell tumor, and perivascular epithelioid cell tumor.
  • This review also describes current theories as to the pathogenesis of inflammatory myofibroblastic tumor and postoperative spindle cell nodule and details the current molecular markers identifying several of these lesions.
  • [MeSH-major] Soft Tissue Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509394.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 87
  •  go-up   go-down


74. Oka M, Fukui T, Ueda M, Tagaya M, Oyama T, Tanaka M: Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction. J Urol; 2009 Jul;182(1):382-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction.
  • PURPOSE: Ischemia/reperfusion injury is a major etiological factor in the progression of bladder dysfunction after partial bladder outlet obstruction and it is partly mediated by the generation of free radicals.
  • The phytotherapeutic agent Eviprostat, a popular treatment for benign prostatic hyperplasia in Japan and Germany, has antioxidant and anti-inflammatory activity.
  • We investigated the effect of Eviprostat on oxidative stress and inflammation in bladder dysfunction in a bladder outlet obstruction rat model.
  • MATERIALS AND METHODS: Bladder outlet obstruction was surgically induced in male rats by placing a rubber ring around the urethra.
  • Rats with bladder outlet obstruction were administered daily oral Eviprostat or vehicle, while sham operated animals were treated with vehicle.
  • On day 6 after surgery bladder weight, oxidative stress markers and proinflammatory cytokine levels as a measure of bladder inflammation, were determined and histological alterations noted.
  • Functional contractility studies were performed with longitudinal bladder strips.
  • RESULTS: Bladder outlet obstruction led to a significant increase in bladder weight, oxidative stress markers and proinflammatory cytokine levels.
  • Eviprostat significantly suppressed these increases without affecting bladder weight.
  • Histological analysis showed increased detrusor muscle hypertrophy and increased numbers of collagen fibers with accompanying inflammatory infiltration in the bladder of vehicle treated bladder outlet obstruction animals.
  • Decreased responses of obstructed bladder strips to electrical stimulation and KCl were ameliorated by Eviprostat treatment.
  • CONCLUSIONS: Eviprostat mediated decrease of the increased oxidative stress and bladder inflammation caused by bladder outlet obstruction may contribute to the protection of bladder function.
  • [MeSH-major] Cystitis / drug therapy. Ethamsylate / pharmacology. Oxidative Stress / drug effects. Plant Extracts / pharmacology. Urinary Bladder Neck Obstruction / drug therapy. Urinary Bladder Neck Obstruction / pathology
  • [MeSH-minor] Animals. Cytokines / metabolism. Disease Models, Animal. Drug Combinations. Immunohistochemistry. Inflammation Mediators / analysis. Interleukin-1beta / metabolism. Male. Phytotherapy / methods. RNA, Messenger / analysis. Random Allocation. Rats. Rats, Sprague-Dawley. Sensitivity and Specificity. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447421.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Drug Combinations; 0 / Inflammation Mediators; 0 / Interleukin-1beta; 0 / Plant Extracts; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 24YL531VOH / Ethamsylate; 59738-67-9 / eviprostat
  •  go-up   go-down


75. Das K, Zhao Y, Sugiono M, Lau W, Tan PH, Cheng C: Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urol Oncol; 2007 Jul-Aug;25(4):317-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
  • Angiogenesis or the development of new blood vessels from the surrounding vasculature is essential for the growth and progression of solid tumors.
  • Vascular endothelial growth factor (VEGF), a positive regulator of angiogenesis, plays a pivotal role in tumor angiogenesis and shows a high expression in almost all known tumors, including transitional cell carcinoma (TCC) of the bladder.
  • We aimed to analyze quantitatively expression of this isoform, VEGF(165)b, in TCC of the bladder and compare it to the benign part of the same organ.
  • A real-time reverse transcriptase polymerase chain reaction protocol was set up to quantitate simultaneously the messenger ribonucleic acid levels of VEGF and VEGF(165)b from 34 clinical samples representing bladder cancer and matched benign tissue.
  • Expression of VEGF(165)b showed a >or=3.0-fold change in 27 of 34 (79%) bladder tumors than the benign samples.
  • Increased expression of VEGF(165)b was seen in superficial tumors as compared to invasive tumors, which was statistically significant (P < 0.001).
  • Therefore, VEGF(165)b was up-regulated in TCC of the bladder.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Gene Expression Regulation, Neoplastic. Urinary Bladder Neoplasms / genetics. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628298.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


76. Shirodkar SP, Lokeshwar VB: Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther; 2008 Jul;8(7):1111-23
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?
  • Bladder cancer is a common malignancy in the USA.
  • Currently, the detection of initial tumors and recurrent disease is based on evaluation of voided urinary specimens, often followed by cystoscopy.
  • As a result, intense work is being done in the field of bladder tumor markers with the goal of identifying bladder cancer earlier, both in the initial diagnosis and in recurrences of known tumor.
  • The possibility of identifying a marker that could noninvasively differentiate benign and malignant causes of hematuria, and identify recurrences prior to their pathologic progression is the objective of this area of research.
  • Currently, a large number of tumor markers exist, each scrutinized in both the laboratory and in clinical trials.
  • Some novel modalities for tumor detection are also presented.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Hematuria / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / urine. Cystoscopy. Humans. Molecular Diagnostic Techniques / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2007;13(3):187-94 [17922047.001]
  • [Cites] J Urol. 2007 Jan;177(1):80-3 [17162008.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):53-61 [10696245.001]
  • [Cites] Int J Oncol. 1993 Oct;3(4):559-63 [21573400.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):35-63 [16399415.001]
  • [Cites] Urology. 2000 Nov 1;56(5):793-7 [11068304.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):52-6 [9933795.001]
  • [Cites] World J Urol. 2008 Feb;26(1):59-65 [17962949.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1701-7 [16541433.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):61-72 [12115318.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):369-73 [14663639.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):884-94 [7666477.001]
  • [Cites] Cancer Pract. 2002 Nov-Dec;10(6):311-22 [12406054.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):52-4 [2045253.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):810-6 [15713770.001]
  • [Cites] J Urol. 2007 Apr;177(4):1277-82; discussion 1282 [17382711.001]
  • [Cites] Urol Oncol. 2006 Nov-Dec;24(6):528-37 [17138134.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):817-24 [15257544.001]
  • [Cites] J Urol. 2003 Jan;169(1):86-9 [12478110.001]
  • [Cites] J Urol. 2007 Feb;177(2):437-43 [17222605.001]
  • [Cites] Urology. 2001 Apr;57(4):680-4 [11306380.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):699-703 [8976763.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2173-9 [17029275.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):293-7 [12209982.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2511-20 [9796985.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):621-30 [14745881.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Urology. 2000 Aug 1;56(2):228-31 [10925083.001]
  • [Cites] Urology. 2003 Jan;61(1):243-7 [12559316.001]
  • [Cites] World J Urol. 2004 Jun;22(2):145-9 [14991320.001]
  • [Cites] J Urol. 1998 Feb;159(2):394-8 [9649246.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 5;119(21):1763-71 [17097029.001]
  • [Cites] J Urol. 2006 Sep;176(3):919-26; discussion 926 [16890655.001]
  • [Cites] World J Urol. 2006 Sep;24(4):418-22 [16688457.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):634-9 [10953114.001]
  • [Cites] J Urol. 2001 Oct;166(4):1280-5 [11547058.001]
  • [Cites] J Urol. 1999 Jul;162(1):53-7 [10379739.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):405-9 [17611663.001]
  • [Cites] J Urol. 2006 Jun;175(6):2032-7; discussion 2037 [16697794.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] World J Urol. 2008 Feb;26(1):45-50 [18180926.001]
  • [Cites] Urology. 2006 Mar;67(3 Suppl 1):25-33; discussion 33-4 [16530072.001]
  • [Cites] Curr Opin Genet Dev. 1991 Dec;1(4):538-43 [1822287.001]
  • [Cites] Semin Diagn Pathol. 1997 May;14(2):123-32 [9179973.001]
  • [Cites] Can J Urol. 1997 Sep;4(3):400-405 [12735818.001]
  • [Cites] Urology. 1998 Nov;52(5):793-6 [9801101.001]
  • [Cites] Med Sci Monit. 2003 Apr;9(4):PI25-9 [12709681.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5352-8 [18048815.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4464-70 [10485499.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jun;134(6):659-65 [18026991.001]
  • [Cites] Urology. 2004 Feb;63(2):392-7 [14972509.001]
  • [Cites] Urology. 2005 Dec;66(6):1256-60 [16360453.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1356-62 [15717321.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1090-3 [17034609.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1280-5 [16287445.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):171-9 [11801555.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):100-4 [15761870.001]
  • [Cites] J Urol. 2000 Jan;163(1):348-56 [10604388.001]
  • [Cites] J Urol. 1996 Oct;156(4):1280-5 [8808854.001]
  • [Cites] Front Biosci. 2002 Jan 01;7:e27-32 [11779714.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):67-72 [11668480.001]
  • [Cites] ScientificWorldJournal. 2006 Mar 27;6:2617-25 [17619739.001]
  • [Cites] Semin Cancer Biol. 1996 Feb;7(1):15-24 [8695762.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Ann Clin Lab Sci. 2006 Winter;36(1):31-8 [16501234.001]
  • [Cites] Am Fam Physician. 2001 Mar 15;63(6):1145-54 [11277551.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):588-97 [12697851.001]
  • [Cites] Asian J Androl. 2007 Sep;9(5):711-5 [17712491.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):845-52 [12808119.001]
  • [Cites] BJU Int. 2008 Jan;101(1):26-9 [17850364.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):83-9 [15389253.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2):75-84 [17382791.001]
  • [Cites] BJU Int. 2007 Feb;99(2):281-5 [17155984.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):131-5 [17321328.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Urology. 2003 Nov;62(5):952-7 [14624933.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):274-80 [15900578.001]
  • [Cites] Urol Int. 2001;66(4):185-90 [11385303.001]
  • [Cites] J Natl Cancer Inst. 1997 May 21;89(10):724-30 [9168188.001]
  • [Cites] Eur Urol. 1990;17(4):281-5 [2364965.001]
  • [Cites] Nat Med. 1997 Jun;3(6):621-4 [9176487.001]
  • [Cites] Urol Oncol. 2001 Jul;6(4):163-169 [11418323.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1106-13 [17311310.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):1971-4 [9817302.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14 [11894002.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 1):1068-72 [17644139.001]
  • [Cites] Urology. 2001 Sep;58(3):367-71 [11549482.001]
  • [Cites] World J Urol. 2007 Dec;25(6):563-71 [17710407.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] World J Urol. 2000 Dec;18(6):401-5 [11204258.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2618-25 [10914702.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1384-91 [14977841.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2914-22 [12115379.001]
  • [Cites] Urology. 2007 Sep;70(3):482-6 [17905101.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Urology. 2007 Sep;70(3):449-53 [17688921.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Urol Clin North Am. 1998 Nov;25(4):661-76 [10026773.001]
  • [Cites] World J Urol. 2008 Feb;26(1):31-7 [18075743.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):329-38 [17373664.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1315-30 [14750899.001]
  • [Cites] Urology. 2000 Feb;55(2):223-6 [10688083.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):25-37 [10696242.001]
  • [Cites] J Urol. 1999 May;161(5):1486-9 [10210378.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):951-6; discussion 956 [16257108.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2052-6 [16249419.001]
  • [Cites] Indian J Med Sci. 2005 Jun;59(6):235-42 [15988093.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):352-7 [17762630.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1388-96 [17466450.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5519-27 [17158537.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):1-8 [18090481.001]
  • [Cites] J Urol. 2007 Jul;178(1):57-61 [17574060.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2333-40 [10873084.001]
  • [Cites] Isr Med Assoc J. 2002 Mar;4(3):174-5 [11908255.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1423-7 [3304614.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):329-43 [15049581.001]
  • [Cites] Int J Urol. 2007 Feb;14(2):108-11 [17302565.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):248-53 [1717095.001]
  • [Cites] J Urol. 2004 Sep;172(3):1123-6 [15311054.001]
  • [Cites] Med Sci Monit. 2003 Aug;9 Suppl 3:25-8 [15156607.001]
  • [Cites] Urology. 2004 Dec;64(6):1121-6 [15596183.001]
  • [Cites] J Urol. 1999 Feb;161(2):443-6 [9915422.001]
  • [Cites] J Urol. 2007 Feb;177(2):481-7; discussion 487 [17222615.001]
  • [Cites] Urology. 1989 Feb;33(2):89-96 [2916296.001]
  • [Cites] Tumour Biol. 2007;28(2):57-62 [17259754.001]
  • [Cites] Eur Urol. 2004 Oct;46(4):466-71 [15363562.001]
  • (PMID = 18588456.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072821; United States / NCI NIH HHS / CA / 5R01 CA-72821-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Number-of-references] 136
  •  go-up   go-down


77. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res; 2006 Dec 15;12(24):7369-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
  • PURPOSE: To determine the association of the cell proliferative marker Ki-67 with pathologic features and disease prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.
  • METHODS: Immunohistochemical staining for Ki-67 was done on serial cuts from tissue microarrays containing cystectomy specimens from 9 patients without bladder cancer and 226 consecutive patients with bladder TCC.
  • In contrast, it was absent in all nine benign cystectomy specimens.
  • In multivariate analyses, pathologic stage and lymph node metastases were independent predictors of disease recurrence and bladder cancer-specific mortality.
  • In the subgroup of patients with organ-confined disease (<pT(3) N(0); n = 91), excluding patients who received neoadjuvant or adjuvant chemotherapy, Ki-67 status was an independent predictor of both disease recurrence (risk ratio, 7.591; P = 0.001) and bladder cancer-specific mortality (risk ratio, 4.045; P = 0.041).
  • CONCLUSIONS: Ki-67 overexpression is associated with features of aggressive bladder TCC and adds independent prognostic information to standard pathologic features for prediction of clinical outcome after radical cystectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Ki-67 Antigen / physiology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / physiology. Cystectomy / statistics & numerical data. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189409.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


78. Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M, Razek OA, El-Ahmady O: Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer; 2005 Apr 1;103(7):1356-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.
  • BACKGROUND: A new, sensitive, noninvasive method for the detection of urothelial carcinomas of the urinary bladder would open new possibilities in both the diagnosis and followup of patients.
  • METHODS: This study included 228 patients diagnosed with bladder carcinoma, 68 patients with benign bladder lesions, and 44 healthy persons served as the control group.
  • RESULTS: HA mean rank was higher in benign and malignant groups than in the healthy group (P < 0.0001) and was significantly related to tumor grade (P = 0.021).
  • CONCLUSIONS: HAase RNA is a promising noninvasive test with high sensitivity and specificity in bladder carcinoma detection.
  • [MeSH-major] Hyaluronoglucosaminidase / urine. Intermediate Filament Proteins / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / urine. Female. Humans. Keratin-20. Male. Middle Aged. Prospective Studies. RNA / urine. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15717321.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 63231-63-0 / RNA; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


79. Taylor JA 3rd, Ristau B, Bonnemaison M, Voznesensky OS, Hegde P, Kuchel GA, Pilbeam CC: Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. Prostaglandins Other Lipid Mediat; 2009 Jan;88(1-2):36-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.
  • Prostaglandin E(2) (PGE(2)) is reported to play an important role in tumor development.
  • We explored the differential expression of genes governing production of, and response to, PGE(2) during development of invasive bladder cancer.
  • Half of each bladder was analyzed histologically and the other half extracted for mRNA analysis by quantitative real-time PCR.
  • Hence, increased COX-2 and decreased PDGH expression occurred throughout tumor development, while mPGES-1, EP2R and EP4R were elevated only before development of invasive cancer.
  • We compared expression of these genes in the malignant human urothelial cell lines, HTB-5 and HT-1376, with expression in a benign urothelial cell line, UROtsa.
  • Neither malignant cell line reproduced the complete in vivo pattern, relative to benign cells, but each showed abnormal basal expression of several of the genes downstream of COX-2, but not COX-2 itself.
  • We conclude that components involved in PGE(2) synthesis and activity are differentially regulated during bladder tumor development and the therapeutic efficacy of targeting the various components may vary with stage of tumor development.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5599-602 [11059745.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Urol Res. 2001 Feb;29(1):20-4 [11310210.001]
  • [Cites] J Bone Miner Res. 2002 Aug;17(8):1430-40 [12162497.001]
  • [Cites] J Urol. 2003 Mar;169(3):938-42 [12576817.001]
  • [Cites] Regul Pept. 2003 Jul 15;114(2-3):101-7 [12832097.001]
  • [Cites] J Urol. 2003 Sep;170(3):985-9 [12913755.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):266-70 [12954496.001]
  • [Cites] Eur Urol. 2003 Oct;44(4):435-41 [14499677.001]
  • [Cites] J Cell Mol Med. 2003 Jul-Sep;7(3):207-22 [14594546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Urology. 2004 Oct;64(4):637-42 [15491687.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):33-6 [8476227.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3785-9 [7641194.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] J Clin Invest. 1997 Sep 15;100(6):1325-9 [9294096.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):11-6 [15596291.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3217-23 [15542609.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2424-30 [10873095.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] J Intern Med. 2005 Aug;258(2):115-23 [16018788.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Clin Genitourin Cancer. 2005 Dec;4(3):203-11 [16425990.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3106-13 [16540660.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 May;74(5):309-15 [16621493.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6649-56 [16818638.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9794-7 [17047037.001]
  • [Cites] J Urol. 2007 Mar;177(3):1163-8 [17296438.001]
  • [Cites] Exp Dermatol. 2007 May;16(5):445-53 [17437488.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2007 May;83(3):203-8 [17481556.001]
  • [Cites] BMC Cancer. 2007;7:135 [17650334.001]
  • [Cites] Carcinogenesis. 1999 Dec;20(12):2305-10 [10590224.001]
  • [Cites] J Clin Invest. 2000 Mar;105(6):823-32 [10727451.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):471-7 [16391871.001]
  • (PMID = 18834948.001).
  • [ISSN] 1098-8823
  • [Journal-full-title] Prostaglandins & other lipid mediators
  • [ISO-abbreviation] Prostaglandins Other Lipid Mediat.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK048361; United States / NIDDK NIH HHS / DK / DK048361-08; United States / NIA NIH HHS / AG / R01AG028657; United States / NIDDK NIH HHS / DK / R01 DK048361-08; United States / NIA NIH HHS / AG / AG028657-02; United States / NIDDK NIH HHS / DK / DK048361-13; United States / NIA NIH HHS / AG / R01 AG028657; United States / NIA NIH HHS / AG / R01 AG028657-02; United States / NIDDK NIH HHS / DK / R01DK48361; United States / NIDDK NIH HHS / DK / R01 DK048361-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prostaglandins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS84408; NLM/ PMC2615552
  •  go-up   go-down


80. Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM: Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst; 2005 Sep;17(3):193-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
  • PURPOSE: The diagnostic efficacy of Nuclear Matrix Protein-22 (NMP-22), bladder tumor antigen (BTA TRAK), and telomerase activity was evaluated in urine in a trial to assess their value in the detection of bladder cancer and to compare it to that of routine urine cytology.
  • SUBJECTS AND METHODS: The study included 46 newly diagnosed bladder cancer patients, diagnosed by cystoscopy and histopathological typing, in addition to 20 patients with benign bladder lesions and 20 healthy age and sex matched volunteers as a control group.
  • The levels of the three parameters were significantly higher in the malignant group compared to either the benign group or normal controls, (p<0.001) and the positive rates were also higher in the malignant group for all 3 parameters.
  • For bilharzial cancer bladder respective sensitivities were 69.6%, 95.6%, 100% and 73.9%, while for nonbilharzial cancer bladder the respective sensitivities were 39.1%, 87%, 100% and 87%.
  • CONCLUSION: BTA showed the highest sensitivity in all the studied parameters in the bladder cancer group, bilharzial bladder cancer subgroup, and non bilharzial bladder subgroup, (100%), while the highest specificity was recorded with urine cytology (100%), followed by telomerase (95%), then BTA (92.5%), and lastly NMP- 22 (87.5%).
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Nuclear Proteins / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / urine. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / urine. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / urine. Female. Humans. Male. Middle Aged. Schistosomiasis haematobia / complications

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799657.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / bladder tumor-associated antigen; 0 / nuclear matrix protein 22; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


81. Gobet R, Weber D, Renzulli P, Kellenberger C: Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome. J Pediatr Urol; 2009 Jun;5(3):190-6
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome.
  • OBJECTIVE: To describe the urological and nephrological long-term outcome of patients born with classical bladder exstrophy treated with bilateral ureterosigmoidostomies in early childhood.
  • PATIENTS AND METHOD: Out of 42 patients born with bladder exstrophy in Switzerland between 1937 and 1968, 25 participated in this study; seven had died, seven were lost to follow up and three refused consent.
  • All others had different forms of urinary diversions.
  • One patient suffered from adenocarcinoma of the colon, five had benign colonic polyps, one urethral papillary carcinoma and 18 no evidence of tumor.
  • [MeSH-major] Bladder Exstrophy / epidemiology. Bladder Exstrophy / surgery. Postoperative Complications / epidemiology. Ureterostomy. Urinary Diversion
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Carcinoma, Papillary / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urination. Urolithiasis / epidemiology

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136304.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Romanenko AM, Kinoshita A, Wanibuchi H, Wei M, Zaparin WK, Vinnichenko WI, Vozianov AF, Fukushima S: Involvement of ubiquitination and sumoylation in bladder lesions induced by persistent long-term low dose ionizing radiation in humans. J Urol; 2006 Feb;175(2):739-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of ubiquitination and sumoylation in bladder lesions induced by persistent long-term low dose ionizing radiation in humans.
  • PURPOSE: We determined whether ubiquitination and sumoylation processes are up-regulated in bladder urothelium by chronic, long-term, persistent low doses of ionizing radiation in male patients with benign prostate hyperplasia and females with chronic cystitis living more than 19 years in 137Cs contaminated areas after the Chernobyl accident in Ukraine.
  • MATERIALS AND METHODS: Bladder urothelial biopsies from 45 patients were subjected to histopathological and immunohistochemical study of Ub, SUMO1, SUMO E2 conjugating enzyme Ubc9, and the cell cycle inhibitors p53 and p27(Kip1).
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Cystitis / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Radiation Injuries / metabolism. SUMO-1 Protein / metabolism. Tumor Suppressor Protein p53 / metabolism. Ubiquitin / metabolism. Ubiquitin-Activating Enzymes / metabolism. Ubiquitin-Conjugating Enzymes / metabolism. Urinary Bladder / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2007 Feb;177(2):794; author reply 794-5 [17222684.001]
  • (PMID = 16407042.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / SUMO-1 Protein; 0 / Tumor Suppressor Protein p53; 0 / Ubiquitin; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 6.3.2.19 / UBA2 protein, human; EC 6.3.2.19 / Ubiquitin-Activating Enzymes; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes; EC 6.3.2.19 / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


83. Tamas EF, Epstein JI: Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains. Am J Surg Pathol; 2007 Mar;31(3):390-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
  • Some patients who have had prior bladder biopsies or transurethral resections undergo a repeat resection within several months for various reasons.
  • The detection of a few residual tumor cells in bladder specimens with prior biopsy site changes can be challenging based on histology alone.
  • We have noted several cases in which keratin stains were performed and positive cells were noted, raising the issue as to whether the cytokeratin positive cells were residual tumor cells or stromal cells.
  • Immunohistochemistry for a panel of antibodies [AE1/AE3, CAM 5.2, high molecular weight cytokeratin, smooth muscle actin (SMA), desmin, and anaplastic lymphoma kinase (ALK)] was performed on 29 cases of bladder biopsies with prior biopsy site changes.
  • Of 29 patients, 25 had a prior history of bladder tumor: 17 had invasive high-grade urothelial carcinoma (T1, 5 cases; T2, 11 cases; T3,1 case); 7 had noninvasive high-grade papillary urothelial carcinoma; 1 had noninvasive low-grade papillary urothelial carcinoma).
  • Four patients had prior benign bladder diagnoses: cystitis cystica et glandularis; polypoid cystitis; follicular cystitis; and neurogenic bladder with benign prostate hyperplasia.
  • These cells were interpreted as residual tumors cells.
  • When interpreting CK stains for the detection of residual tumor cells, one should pay attention to the nature of the cells and not assume all CK staining cells are residual tumor cells.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Diagnostic Errors / prevention & control. Keratins / analysis. Neoplasm, Residual / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325480.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


84. Haylen BT: The empty bladder. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Mar;18(3):237-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The empty bladder.
  • The empty (near-empty) bladder can have a volume ranging from 0 to 30 ml.
  • Its diagnosis is effectively and least invasively made by ultrasound (transvaginal superior).
  • It is a key marker of normal bladder function.
  • It is necessary for the accurate assessment of uterovaginal prolapse, as increasing bladder volume has been shown to reduce the extent of the prolapse.
  • Any negative effect of prolapse on voiding is reduced at high bladder volumes compared to voiding from low bladder volumes (due to the same reduction in the extent of the prolapse).
  • An empty bladder is optimal for bimanual pelvic examination and most transvaginal ultrasound examinations including that for uterine version.
  • The woman whose bladder is empty post-voiding is at a significantly lower risk of recurrent urinary tract infections.
  • The bladder that can't be emptied is a marker of bladder dysfunction, requiring a fuller investigation.
  • From a surgical point of view, the empty bladder improves access and reduces surgical risks with laparotomy, as well as both laparoscopic and vaginal surgery.
  • [MeSH-major] Urinary Bladder / physiology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Recurrence. Urinary Tract Infections / physiopathology. Urination / physiology. Uterine Prolapse / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791705.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM: Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J Urol; 2007 Sep;178(3 Pt 1):1068-72
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer.
  • PURPOSE: New, noninvasive methods are needed for the diagnosis, followup and screening of patients with bladder cancer.
  • MATERIALS AND METHODS: This study included 200 patients diagnosed with bladder carcinoma, 85 with benign bladder lesions and 30 healthy individuals who served as the control group.
  • Results were significantly higher in the malignant group than in the benign and control groups.
  • Overall the sensitivity of human telomerase reverse transcriptase for detecting bladder cancer was the highest compared to that of human telomerase RNA, relative telomerase activity and urine cytology (96%, 92%, 75% and 75%, respectively).
  • CONCLUSIONS: Detection of human telomerase reverse transcriptase in urine by real-time polymerase chain reaction, followed by human telomerase RNA by reverse transcriptase-polymerase chain reaction, improves sensitivity and specificity for the diagnosis of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644139.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


86. Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int; 2008;81(3):320-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
  • OBJECTIVE: To investigate the clinical significance of E-cadherin (E-CD) expression in human bladder transitional cell carcinoma (TCC) tissue and soluble forms of E-cadherin (sE-CD) in the urine of patients with TCC.
  • MATERIALS AND METHODS: One hundred and two specimens of bladder TCC and 10 normal bladder tissues were stained immunohistochemically with anti-E-CD monoclonal antibody.
  • The urinary sE-CD from 59 subjects with TCC or controls was measured with enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The expression of E-CD in bladder TCC correlated well with grade and stage but had no significant correlation with the size or number of the tumors.
  • Normal expression rate of E-CD is significantly higher in primary than in recurrent tumors.
  • The level of urinary sE-CD was higher in patients with TCC than in normal controls or patients with benign disorders of the urinary system.
  • Urinary sE-CD levels were strongly correlated with tumor grade but showed no significant correlation with the stage, size and number of the tumors.
  • The urinary sE-CD level is significantly higher in the recurrent group than in the primary group.
  • CONCLUSIONS: Expression of E-CD in the tissue of TCC and the urinary level of sE-CD are very closely associated with the biological behaviors of bladder TCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Transitional Cell / chemistry. Urinary Bladder Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18931551.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


87. Dilbaz B, Bayoglu Y, Oral S, Cavusoglu D, Uluoglu O, Dilbaz S: Laparoscopic resection of urinary bladder paraganglioma: a case report. Surg Laparosc Endosc Percutan Tech; 2006 Feb;16(1):58-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection of urinary bladder paraganglioma: a case report.
  • The case report of a 55-year-old woman with an incidentally diagnosed urinary paraganglioma of the bladder is presented.
  • Transvaginal ultrasonography revealed a well-limited ovoid mass with solid and cystic areas adjacent to the urinary bladder and the uterus.
  • Tumor markers were within normal range.
  • Frozen section was performed revealing a benign cystic structure but the identification of the origin was left to definitive histopathological examination which showed paraganglioma of the bladder.
  • Immunohistochemically, the tumor cells were strongly positive for chromogranin A and synaptophysin and there was focal positiveness for neuron specific enolase although vimentin and cytokeratin were negative.
  • [MeSH-major] Paraganglioma / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552385.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Dong L, Bard AJ, Richards WG, Nitz MD, Theodorescu D, Bueno R, Gordon GJ: A gene expression ratio-based diagnostic test for bladder cancer. Adv Appl Bioinform Chem; 2009;2:17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gene expression ratio-based diagnostic test for bladder cancer.
  • PURPOSE: Bladder cancer is relatively common but early detection techniques such as cystoscopy and cytology are somewhat limited.
  • In this study, we sought to determine whether this technique could be applied to the diagnosis of bladder cancer.
  • EXPERIMENTAL DESIGN: We developed a model for the diagnosis of bladder cancer using expression profiling data from 80 normal and tumor bladder tissues to identify statistically significant discriminating genes with reciprocal average expression levels in each tissue type.
  • The expression levels of select genes were used to calculate individual gene pair expression ratios in order to assign diagnosis.
  • The optimal model was examined in two additional published microarray data sets and using quantitative RT-PCR in a cohort of 13 frozen benign bladder urothelium samples and 13 bladder cancer samples from our institution.
  • RESULTS: A five-ratio test utilizing six genes proved to be 100% accurate (26 of 26 samples) for distinguishing benign from malignant bladder tissue samples (P < 10(-6)).
  • CONCLUSIONS: : We have provided a proof of principle study for the use of gene expression ratios in the diagnosis of bladder cancer.
  • This technique may ultimately prove to be a useful adjunct to cytopathology in screening urine specimens for bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):905-10 [14504202.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):903-6 [14713850.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):778-89 [16432078.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7813-21 [15520187.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):853-60 [12576459.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Jpn J Cancer Res. 2002 Apr;93(4):389-96 [11985788.001]
  • [Cites] Nat Rev Genet. 2001 Jun;2(6):418-27 [11389458.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):4-5 [10973232.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Sep;132(3):621-7 [16935118.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1347-55; discussion 1355-6 [16815626.001]
  • [Cites] BMC Cancer. 2005;5:73 [16000172.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4406-14 [15958625.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • (PMID = 21918612.001).
  • [ISSN] 1178-6949
  • [Journal-full-title] Advances and applications in bioinformatics and chemistry : AABC
  • [ISO-abbreviation] Adv Appl Bioinform Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3169945
  • [Keywords] NOTNLM ; and diagnosis / bladder cancer / gene expression profiling
  •  go-up   go-down


89. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE: Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics; 2010;3:58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder.
  • BACKGROUND: Urothelial carcinoma (UC) can arise at any location along the urothelial tract, including the urethra, bladder, ureter, or renal pelvis.
  • Although tumors arising in these various locations have similar morphology, it is unclear whether the gene expression profiles are similar between the upper-tract (ureter and renal pelvis) and lower-tract (bladder and urethra) carcinomas.
  • Because differences may facilitate different screening and treatment modalities, we sought to examine the relationship between urothelial carcinoma of the renal pelvis (rUC) and urothelial carcinoma of the bladder (bUC).
  • METHODS: Fresh tumor tissue was collected from patients with bUC (n = 10) and benign mucosa from the bladder of individuals undergoing resection for non-UC conditions (n = 7).
  • CONCLUSIONS: We found that the gene expression profiles of UCs from the upper and lower tract were extremely similar, suggesting that similar pathogenic mechanisms likely function in the development of these tumors.
  • The differential expression of genes in the identified pathway may represent a new avenue for detection of upper-tract tumors.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Profiling. Kidney Neoplasms / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Genetic Markers. Humans. Urinary Tract / pathology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):59-63 [11408067.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40510-7 [11483609.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8241-6 [11719456.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2872-80 [12782593.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bioinformatics. 2004 Jan 22;20(2):289-90 [14734327.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1474-80 [14973555.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2250-63 [14968109.001]
  • [Cites] Br J Urol. 1991 Jan;67(1):32-6 [1993274.001]
  • [Cites] Virchows Arch. 2006 May;448(5):604-11 [16525827.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jan;46(1):75-86 [17044051.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1346-50 [17322920.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3171-6 [17409424.001]
  • [Cites] J Urol. 2007 May;177(5):1715-20 [17437794.001]
  • [Cites] PLoS Genet. 2008;4(9):e1000176 [18773095.001]
  • [Cites] Mutat Res. 2008 Nov 17;657(1):77-83 [18790077.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4674-81 [19470766.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] Urol Res. 1996;24(4):239-44 [8873383.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1545-52 [15577672.001]
  • [Cites] BMC Genomics. 2005;6:67 [15882461.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5740-7 [16115911.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):272-9 [16424895.001]
  • (PMID = 21159190.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC3022544
  •  go-up   go-down


90. Siatelis A, Konstantinidis C, Volanis D, Leontara V, Thoma-Tsagli E, Delakas D: Pheochromocytoma of the urinary bladder: report of 2 cases and review of literature. Minerva Urol Nefrol; 2008 Jun;60(2):137-40
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma of the urinary bladder: report of 2 cases and review of literature.
  • Pheochromocytoma of the urinary bladder is a rare neoplasm of the chromaffin tissue of the sympathetic nervous system within the layers of the bladder wall.
  • It accounts for less than 0.06% of all urinary bladder tumors and less than 1% of all pheochromocytomas.
  • The diagnosis is strongly based on the clinical symptoms related to catecholamine hypersecretion.
  • In some cases however, the tumor is hormonally inactive and may go undetected for years.
  • The cytologic features of benign and malignant tumors overlap and thus there are no reliable features of malignancy.
  • Nevertheless the prognosis seems to be better for patients with superficial tumors comparing to patients with invasive tumors, found in 5-10% of cases.
  • For metastatic tumors, chemotherapy and radiotherapy seem to be effective.
  • The authors present two new cases of pheochromocytoma of the urinary bladder.
  • The authors discuss the difficulties in diagnosis and treatment and briefly review literature.
  • [MeSH-major] Pheochromocytoma. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500228.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 12
  •  go-up   go-down


91. Tsui KH, Chen SM, Wang TM, Juang HH, Chen CL, Sun GH, Chang PL: Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl; 2007 Sep;9(5):711-5
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China.
  • AIM: To compare the results of bladder tumor associated antigen (BTA TRAK), nuclear matrix protein 22 (NMP 22) and voided urine cytology (VUC) in detecting bladder cancer.
  • METHODS: A total of 135 elderly male and 50 healthy volunteers enrolled in this study were classified into three groups: (i) 93 patients with bladder cancer;.
  • (ii) 42 patients with urinary benign conditions; and (iii) 50 healthy volunteers.
  • BTA TRAK and NMP 22 kits were used to detect bladder cancer.
  • The level of NMP 22 increased with tumor grading.
  • The NMP 22 with the best sensitivity can be an adjunct to cytology for evaluating bladder cancer.
  • CONCLUSION: The NMP 22 test has a better correlation with the grading of the bladder cancer than BTA TRAK.
  • As cytology units are typically not available in hospitals or in outpatient clinics, NMP 22 might be a promising tool for screening bladder cancer.
  • [MeSH-major] Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine. Urine / cytology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712491.001).
  • [ISSN] 1008-682X
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


92. Lee SH, Mah SY, Chung BH: Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms. J Endourol; 2010 Feb;24(2):271-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms.
  • BACKGROUND AND PURPOSE: Inverted urothelial papilloma (IP) is an uncommon urothelial neoplasm.
  • We aimed to determine the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and lower urinary tract symptoms (LUTS).
  • PATIENTS AND METHODS: From 1994 to 2008, 53 patients with urinary IP underwent transurethral resection of the bladder tumor (TURBT) at our institution.
  • We reviewed the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and LUTS.
  • In IP located on the bladder neck of patients with benign prostatic hyperplasia (BPH), significantly higher obstructive symptoms and larger prostate volumes than that of other located IP with BPH were observed.
  • CONCLUSIONS: This is the largest series of cases of urinary bladder IP reported from Korea.
  • Despite the absence of agreement of its etiology, its presenting symptoms were related to LUTS and benign prostatic enlargement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20039831.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Bai SW, Jung HJ, Jeon MJ, Jung DJ, Kim SK, Kim JW: Leiomyomas of the female urethra and bladder: a report of five cases and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Aug;18(8):913-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyomas of the female urethra and bladder: a report of five cases and review of the literature.
  • Through the experience of five cases of leiomyoma developed in the female bladder and urethra with a review of the literature, we have made an effort to characterize the association of symptom with the size and location of the tumor and demonstrate an appropriate treatment.
  • The study population was composed of patients who underwent surgery for bladder or urethral leiomyoma in our hospital from March 1990 to April 2005.
  • Four cases were diagnosed as urethral leiomyoma and one case as bladder leiomyoma.
  • All patients with urethral leiomyoma were admitted for the chief complaint of a palpable tumor.
  • When the tumor size was small, if it was located on the lateral side of the urethra, it was asymptomatic, but if located in the midline, it presented irritative or obstructive symptom.
  • One case of bladder leiomyoma was discovered incidentally during ultrasonic exam.
  • Bladder and urethral leiomyomas are very rare and cause diverse manifestations from asymptomatic to irritative or obstructive symptom.
  • It is presumed that the location and size of the tumor are associated with symptom.
  • However, it is desirable to distinguish leiomyoma from malignant or other benign tumors by surgical biopsy or removal.
  • [MeSH-major] Leiomyoma / pathology. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Retrospective Studies. Urethra / pathology. Urethra / surgery. Urinary Bladder / pathology. Urinary Bladder / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333443.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


94. Ceylan K, Taken K, Gecit I, Pirincci N, Gunes M, Tanik S, Karaman I: Comparison of cystoscopy with diffusion-weighted magnetic resonance images used in the diagnosis and follow-up of patients with bladder tumors. Asian Pac J Cancer Prev; 2010;11(4):1001-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cystoscopy with diffusion-weighted magnetic resonance images used in the diagnosis and follow-up of patients with bladder tumors.
  • PURPOSE: To compare diffusion-weighted magnetic resonance imaging (DW-MRI) with cystoscopy in the diagnosis and follow-up of patients with bladder tumor and to investigate any histopathological correlation.
  • MATERIALS AND METHODS: Totally 59 patients, between 31-85 years (mean age 60∓13) referred to our clinic due to a hematuria complaint were enrolled and evaluated by upper urinary system pathology and then DW-MRI (average 7 days) and cystoscopy.
  • RESULTS: While a mass in bladder was determined with cystoscopy in 43 out of 59 patients,the mass was not determined in 16 of the patients (n=34 malign, n=9 benign).
  • While a mass was determined in 40 out of 59 patients with DW-MRI,the mass was not determined in 19 of the patients(n=40 malign, n=19 benign).
  • Regarding ADC values, mean ADC values of 34 patients who were diagnosed with a bladder tumor (1.05∓0.22x10(-3) mm2/s), were significantly lower than the mean ADC values obtained from the normal bladder wall (1.830∓0.18x10(-3) mm2/s) whereas a statistically significant difference was found (p<0.001).
  • ADC values in 9 patients with a benign lesion (1.73∓0.12x10(-3) mm2/s), were not found statistically different from the mean ADC values obtained from the normal bladder wall (1.78∓0.2x10(-3) mm2/s) (p>0.05).
  • A significant difference was determined between ADC values of benign lesions and the ADC values of malign lesions (p<0.001).
  • As the DW-MRI is a non-invasive and a rapid technique, and does not contain ionized radiation and because it is accepted as an important marker of tumor cellularity, it may be used as an alternative in future diagnosis and follow-up of bladder tumors.
  • [MeSH-major] Cystoscopy. Diffusion Magnetic Resonance Imaging. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133614.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


95. Juan Escudero JU, Ramos de Campos M, Ordoño Domínguez F, Fabuel Deltoro M, Serrano de la Cruz Torrijos F, Navalón Verdejo P, López Alcina E, Zaragoza Orts J: [Inguinoscrotal bladder hernias]. Arch Esp Urol; 2007 Apr;60(3):231-6
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinoscrotal bladder hernias].
  • In the general population, only a small percentage of them involve the bladder.
  • Bladder wall weakness and bladder outlet obstruction are involved in its pathogenesis.
  • We present our experience in the diagnosis and treatment of this rare disease.
  • METHODS: A total of eight patients have been diagnosed of inguinoscrotal bladder hernia and treated in our center over the last 18 years.
  • In most cases, retrograde and voiding cystourethrograms, prostatic and bladder ultrasound, and uroflowmetry have been performed.
  • The treatment varied depending on the characteristics of the herniated bladder tissues and bladder capacity.
  • The treatment of bladder outlet obstruction varied depending on the etiology.
  • Resection of the herniated bladder tissue was carried out in four patients due to the quality of the tissue; bladder-pexy to the abdominis rectus muscles was performed in one patient; hernia repair with bladder reintroduction was the treatment in the other four cases.
  • Bladder outlet obstruction was treated in six cases.
  • Seven patients showed clinical improvement, showing normal bladder morphology on post operative cystogram.
  • CONCLUSIONS: Bladder hernia is a rare pathology often presenting in mid age males.
  • It should be suspected in every male with lower urinary tract obstructive symptoms and associated inguinal hernia.
  • The treatment of choice is that of the hernia and bladder outlet obstruction.
  • [MeSH-major] Genital Diseases, Male / diagnosis. Genital Diseases, Male / surgery. Hernia, Inguinal / diagnosis. Hernia, Inguinal / surgery. Scrotum. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601297.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


96. Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, Gromova I: Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics; 2010 Jan;9(1):161-77
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
  • It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors.
  • As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer.
  • Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10.
  • To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up.
  • We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Proteomics / methods. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2891-3 [11686292.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):495-503 [11601134.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):539-46 [11920613.001]
  • [Cites] Neuron. 2002 Apr 25;34(3):349-56 [11988167.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):269-79 [12096109.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3759-64 [12552989.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Science. 2003 Aug 8;301(5634):832-6 [12907802.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):801 [14985749.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):410-9 [14736829.001]
  • [Cites] Pharmacogenomics. 2004 Jun;5(4):381-94 [15165174.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Sep;19(5):465-6 [15169658.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Acta Chir Scand. 1965 Oct;130(4):371-8 [5842510.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;391(2):217-25 [6784337.001]
  • [Cites] Cell. 1991 Oct 4;67(1):11-9 [1717158.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1677-80 [7502080.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Nature. 1997 May 15;387(6630):303-8 [9153397.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4111-7 [9307301.001]
  • [Cites] Int J Oncol. 1998 Aug;13(2):379-83 [9664136.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):241-8 [10197429.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] Hybrid Hybridomics. 2004 Dec;23(6):335-42 [15684659.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1162-8 [15731336.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):570-81 [15734831.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):1853-8 [15691854.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2590-5 [15797904.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W226-9 [15980458.001]
  • [Cites] Tumour Biol. 2006;27(4):221-6 [16675915.001]
  • [Cites] Ai Zheng. 2006 Jul;25(7):811-7 [16831269.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1071 [17129789.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):185-93 [17310252.001]
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):81-92 [17031575.001]
  • [Cites] Genome Res. 2007 Nov;17(11):1586-95 [17908822.001]
  • [Cites] J Clin Epidemiol. 2007 Dec;60(12):1205-19 [17998073.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):7251-60 [18178553.001]
  • [Cites] RNA. 2008 Jun;14(6):1110-8 [18430892.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:1-12 [18519955.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):554-6 [18538738.001]
  • [Cites] Urology. 2008 Sep;72(3):706-10 [18342921.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Tumour Biol. 2008;29(5):311-22 [18984977.001]
  • [Cites] RNA Biol. 2008 Oct-Dec;5(4):193-7 [18971634.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):384-94 [19383312.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):406-12 [19383314.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Urol Oncol. 2011 Jan-Feb;29(1):21-6 [19186082.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4079-84 [10632343.001]
  • [Cites] EXS. 2000;88:55-67 [10803371.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):726-32 [11072240.001]
  • [Cites] J Mol Biol. 2001 Jan 19;305(3):567-80 [11152613.001]
  • [Cites] J Pathol. 2001 Jul;194(3):349-57 [11439368.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 [11717408.001]
  • (PMID = 19783793.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BLCAP protein, human; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2808262
  •  go-up   go-down


97. Hazzaa SM, Elashry OM, Afifi IK: Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res; 2010 Mar;16(1):101-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder.
  • We investigated the feasibility of profiling and measuring the concentration of clusterin in urine and serum for individuals with transitional cell carcinoma (TCC) of the bladder and comparing it with nontumor controls.
  • In addition, we analyzed the correlation of expression of clusterin in specimens of TCC to various clinicopathologic parameters and prognosis of bladder cancer.
  • Blood and urine samples were used from 68 patients with TCC of the bladder and from 61 patients with benign urological diseases.
  • Quantitation of clusterin mRNA was carried out in 68 bladder tumor specimens from radical cystectomy or transurethral resection and 26 normal bladder specimens from BPH patients by using RT-PCR method.
  • Serum and urine clusterin was significantly higher in individuals with bladder cancer than control (p = 0.001).
  • Sensitivity and specificity of serum and urine clusterin as a tumor marker for TCC of the bladder was found to be 80%, 91%, 87.1% and 96.7% respectively.
  • Expression of clusterin was significantly higher in patients with invasive TCC of the bladder than that in patients with superficial TCC and control (P < 0.001).
  • Overexpression of clusterin mRNA was significantly associated with tumor recurrence and overall survival (p < 0.001).
  • Clusterin may be considered as a potential diagnostic and prognostic biomarker for bladder cancer using urine, serum and/or molecular biology techniques.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Clusterin / biosynthesis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757199.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Clusterin
  •  go-up   go-down


98. Campobasso P, Fasoli L, Dante S: Sodium hyaluronate in treatment of diffuse nephrogenic adenoma of the bladder in a child. J Pediatr Urol; 2007 Apr;3(2):156-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sodium hyaluronate in treatment of diffuse nephrogenic adenoma of the bladder in a child.
  • Nephrogenic adenoma is a rare, benign lesion of the bladder, occurring as an epithelial response to chronic infection or trauma, probably arising from nephrogenic metaplasia.
  • In contrast to nephrogenic adenomas in adults, who present with this tumor in the entire ureteral tract, it has been observed exclusively in the bladder of children thus far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947724.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Kiuchi H, Takao T, Yamamoto K, Nakayama J, Miyagawa Y, Tsujimura A, Nonomura N, Okuyama A: Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation. J Urol; 2009 May;181(5):2339-48
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
  • Evidence suggests that tumor necrosis factor-alpha (R&D Systems), interleukin-1beta and cyclooxygenase-2 are directly involved in the pathogenesis of cyclophosphamide induced cystitis and these molecules depend on transcription factor NF-kappaB for maximal secretion.
  • We determined whether parthenolide could be used as a preventive agent for hemorrhagic cystitis and bladder overactivity.
  • Moreover, we determined the molecular mechanisms of parthenolide on the inhibitory action of nuclear factor-kappaB in inflammatory human benign urothelial cells.
  • Human urothelial cells were pretreated with parthenolide and stimulated with tumor necrosis factor-alpha.
  • RESULTS: Parthenolide pretreatment inhibited bladder inflammation as well as bladder overactivity and it was also associated with nuclear factor-kappaB activation in the bladder.
  • Parthenolide dose dependently suppressed tumor necrosis factor-alpha induced cyclooxygenase-2 expression and prevented nuclear factor-kappaB phosphorylation as well as nuclear factor-kappaB nuclear translocation and IkappaBalpha phosphorylation/degradation.
  • Parthenolide ameliorates bladder inflammation and bladder overactivity, and it might be a promising agent for preventing cyclophosphamide induced complications.
  • [MeSH-major] Cyclophosphamide / adverse effects. Cystitis / prevention & control. NF-kappa B / metabolism. Sesquiterpenes / pharmacology. Urinary Bladder, Overactive / prevention & control

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 May;181(5):1987-8 [19286223.001]
  • (PMID = 19303104.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Sesquiterpenes; 2RDB26I5ZB / parthenolide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


100. Sánchez Merino JM, Guillán Maquieira C, Galán Ramos J, Valerdiz Casasola S, Parra Muntaner L, Gómez Cisneros SC, García Alonso J: [Bladder leiomyoma. A case report and literature review]. Arch Esp Urol; 2005 Nov;58(9):950-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder leiomyoma. A case report and literature review].
  • [Transliterated title] Leiomioma vesical.
  • OBJECTIVES: To report a new case of bladder leiomyoma.
  • METHODS: A 20 mm tumor of the right lateral wall of the bladder was incidentally found in a pelvic ultrasound study of a 29-year-old female.
  • Cystoscopy showed a right lateral wall tumor with normal mucosal cover.
  • RESULTS: With the working diagnosis of bladder leiomyoma, transurethral resection of the bladder tumor was performed, and pathology confirmed the diagnosis.
  • CONCLUSION: Although it is a rare tumor, in certain circumstances it is possible to establish the working preoperative diagnosis with a high index of suspicion.
  • On the other hand, due to the benign character of the process, conservative surgery (transurethral resection in this case) offers excellent results.
  • [MeSH-major] Leiomyoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430044.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 25
  •  go-up   go-down






Advertisement